var title_f43_29_44496="Eastman retractor";
var content_f43_29_44496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eastman modification of the Richardson retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44496=[""].join("\n");
var outline_f43_29_44496=null;
var title_f43_29_44497="Perioral dermatitis in child";
var content_f43_29_44497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Perioral dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present around the oral cavity in this child. Note the relative sparing of skin around the border of the lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission of Edizioni Minerva Medica from G Ital Dermatol Venereol 2010; 145:433. Copyright &copy; 2010. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44497=[""].join("\n");
var outline_f43_29_44497=null;
var title_f43_29_44498="Cartilage inflammation in RPC";
var content_f43_29_44498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cartilage inflammation in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Advancing disease with granulation tissue invading and replacing regions of cartilage (arrows), leading to the creation of sequestered islands in a patient with relapsing polychondritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome H Herman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44498=[""].join("\n");
var outline_f43_29_44498=null;
var title_f43_29_44499="Cyclizine: Patient drug information";
var content_f43_29_44499=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyclizine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/54/32612?source=see_link\">",
"     see \"Cyclizine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bonine&reg; for Kids [OTC] [DSC];",
"     </li>",
"     <li>",
"      Cyclivert&reg; [OTC];",
"     </li>",
"     <li>",
"      Marezine&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help motion sickness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cyclizine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for motion sickness, take 30 minutes before travel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12344 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44499=[""].join("\n");
var outline_f43_29_44499=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155210\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030469\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030468\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030473\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030474\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030476\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030471\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030472\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030477\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030478\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/54/32612?source=related_link\">",
"      Cyclizine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_29_44500="Pegvisomant: Patient drug information";
var content_f43_29_44500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pegvisomant: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/23/24948?source=see_link\">",
"     see \"Pegvisomant: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Somavert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6133105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Somavert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat acromegaly.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702692",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pegvisomant or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697203",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may lower blood sugar. High blood sugar drugs may need to be changed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699226",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Once mixed, use right away. You may keep at room temperature for up to 6 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11182 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44500=[""].join("\n");
var outline_f43_29_44500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207047\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6133105\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028088\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028087\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028092\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028093\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028095\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028090\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028091\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028096\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028097\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/23/24948?source=related_link\">",
"      Pegvisomant: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_29_44501="Cisatracurium: Pediatric drug information";
var content_f43_29_44501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cisatracurium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"    see \"Cisatracurium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/60/34755?source=see_link\">",
"    see \"Cisatracurium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nimbex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nimbex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Neuromuscular Blocker Agent, Nondepolarizing",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Paralytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"      see \"Cisatracurium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Paralysis/skeletal muscle relaxation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children 1-23 months: 0.15 mg/kg over 5-10 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;2 years and Adolescents: 0.1-0.15 mg/kg over 5-10 seconds (Martin, 1999; Playfor, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Initial: 0.15-0.2 mg/kg followed by maintenance dose of 0.03 mg/kg 40-65 minutes later or as needed to maintain neuromuscular blockade",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Continuous I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: 1-4",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute (0.06-0.24 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); 3.9 &plusmn; 1.3",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute (0.23 &plusmn; 0.08 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) was the mean infusion rate needed to maintain neuromuscular blockade in 19 children (ages 3 months to 16 years) (Burnmester, 2005; Martin, 1999; Playfor, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1-3",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute (0.06-0.18 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     );",
"     <b>",
"      Note:",
"     </b>",
"     There may be wide interpatient variability in dosage (range: 0.5-10",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute in adults) which may increase and decrease over time; optimize patient dosage by utilizing a peripheral nerve stimulator",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2 mg/mL (5 mL, 10 mL); 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nimbex&reg;: 2 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nimbex&reg;: 2 mg/mL (10 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nimbex&reg;: 10 mg/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. May be administered without further dilution by rapid I.V. injection over 5-10 seconds; for continuous I.V. infusions, dilute to a final concentration of 0.1-0.4 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; not for I.M. injection due to tissue irritation",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F152201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alfentanil, amikacin, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, chlorpromazine, cimetidine, ciprofloxacin, clindamycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diphenhydramine, dobutamine, dopamine, doxycycline, droperidol, drotrecogin alfa, enalaprilat, epinephrine, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, gentamicin, haloperidol, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, inamrinone, isoproterenol, ketorolac, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, metoclopramide, metronidazole, midazolam, minocycline, morphine, nalbuphine, nitroglycerin, norepinephrine, ondansetron, palonosetron, phenylephrine, potassium chloride, procainamide, prochlorperazine edisylate, promethazine, ranitidine, remifentanil, sufentanil, theophylline, tobramycin, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, micafungin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, aminophylline, amphotericin B, ampicillin, ampicillin/sulbactam, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, diazepam, furosemide, ganciclovir, heparin, methylprednisolone sodium succinate, nitroprusside, piperacillin, piperacillin/tazobactam, propofol, sodium bicarbonate, sulfamethoxazole/trimethoprim,  thiopental, ticarcillin/clavulanate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light; do not freeze. Use vials within 21 days upon removal from the refrigerator to room temperature (25&deg;C to 77&deg;F); unstable in alkaline solutions;",
"     <b>",
"      compatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, and NS; per the manufacturer, do not dilute in LR; dilutions of 0.1-0.2 mg/mL in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W are stable for up to 24 hours at room temperature or under refrigeration and in D",
"     <sub>",
"      5",
"     </sub>",
"     LR for up to 24 hours in the refrigerator.",
"     <i>",
"      Additional stability data:",
"     </i>",
"     Dilutions of 0.1, 2, and 5 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS are stable in the refrigerator for up to 30 days; at room temperature (23&ordm;C), dilutions of 0.1 and 2 mg/mL began exhibiting substantial drug loss between 7-14 days; dilutions of 5 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS are stable for up to 30 days at room temperature (23&ordm;C) (Xu, 1998);",
"     <b>",
"      incompatible",
"     </b>",
"     for Y-site administration with propofol or ketorolac;",
"     <b>",
"      compatible",
"     </b>",
"     for Y-site administration with sufentanil, alfentanil, fentanyl, midazolam, and droperidol.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to general anesthesia, to facilitate endotracheal intubation, and provide  skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in ages 1 month to 12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nimbex&reg; may be confused with NovoLOG&reg;, Revex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F152200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Effects are minimal and transient: Acute quadriplegic myopathy syndrome (prolonged use), bradycardia, bronchospasm, flushing, hypotension, myositis ossificans (prolonged use), pruritus, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cisatracurium or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Certain clinical conditions may result in potentiation or antagonism of neuromuscular blockade, see table. Increased sensitivity in patients with myasthenia gravis, Eaton-Lambert syndrome, resistance to neuromuscular blockade in burn patients (&gt;30% of body) for period of 5-70 days postinjury; resistance to neuromuscular blockade in patients with muscle trauma, denervation, immobilization, infection. When used in conjunction with anesthetics, bradycardia may be more common with cisatracurium than with other neuromuscular-blocking agents; it has no clinically significant effects on heart rate to counteract the bradycardia produced by anesthetics.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Clinical Conditions Affecting Neuromuscular Blockade",
"     </caption>",
"     <col align=\"left\" width=\"240\">",
"     </col>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Potentiation",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Antagonism",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Acidosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Acute intermittent porphyria",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Electrolyte abnormalities",
"        </p>",
"        <p style=\"text-indent:2em;\">",
"         Hypermagnesemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hypocalcemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hypokalemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hyponatremia",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Hepatic failure",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Neuromuscular diseases",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Renal failure",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Alkalosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Demyelinating lesions",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Diabetes mellitus",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Hypercalcemia",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Peripheral neuropathies",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ventilation must be supported during neuromuscular blockade; cisatracurium should only be administered by individuals who are experienced in the maintenance of an adequate airway and respiratory support. Due to its intermediate onset of action, cisatracurium is not recommended for rapid sequence intubation. Cisatracurium does not alter consciousness; use in conjunction with adequate sedation or anesthesia. Severe allergic reactions have been reported with neuromuscular blocking agents including cisatracurium; cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some multiple use vials (10 mL) may contain benzyl alcohol as a preservative; benzyl alcohol may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; avoid use of vials containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Muscle twitch response to peripheral nerve stimulation, heart rate, blood pressure, assisted ventilation status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Within 2-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Dose dependent, 35-45 minutes after a single 0.1 mg/kg dose; recovery begins in 20-35 minutes when anesthesia is balanced; recovery is attained in 90% of patients in 25-93 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Some metabolites are active; 80% of drug clearance is via a rapid nonenzymatic degradation (Hofmann elimination) in the bloodstream; additional metabolism occurs via ester hydrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 22-31 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;10% of dose excreted as unchanged drug in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 5.9 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 5.1 mL/kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1057404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neuromuscular blocking potency is 3 times that of atracurium; maximum block is up to 2 minutes longer than for equipotent doses of atracurium; laudanosine, a metabolite without neuromuscular blocking activity has been associated with hypotension and seizure activity in animal studies.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burmester M and Mok Q, \"Randomised Controlled Trial Comparing Cisatracurium and Vecuronium Infusions in a Paediatric Intensive Care Unit,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2005, 31(5):686-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44501/abstract-text/15815895/pubmed\" id=\"15815895\" target=\"_blank\">",
"        15815895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin LD, Bratton SL, and O'Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(7):1358-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44501/abstract-text/ 10446832 /pubmed\" id=\" 10446832 \" target=\"_blank\">",
"        10446832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Playfor S, Jenkins I, Boyles C, et al, \"Consensus Guidelines for Sustained Neuromuscular Blockade in Critically Ill Children,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2007, 17(9):881-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44501/abstract-text/17683408/pubmed\" id=\"17683408\" target=\"_blank\">",
"        17683408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Xu QA, Zhang YP, Trissel LA, et al, \"Stability of Cisatracurium Besylate in Vials, Syringes, and Infusion Admixtures,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55(10):1037-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44501/abstract-text/9606456/pubmed\" id=\"9606456\" target=\"_blank\">",
"        9606456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13160 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44501=[""].join("\n");
var outline_f43_29_44501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152161\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152162\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057396\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057390\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152143\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152129\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057399\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152201\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057393\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057398\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152203\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152200\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057403\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057389\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057388\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299048\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152137\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152139\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494843\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057395\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057387\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057401\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057402\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057404\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13160\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13160|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=related_link\">",
"      Cisatracurium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/60/34755?source=related_link\">",
"      Cisatracurium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_29_44502="Central sleep apnea: Risk factors, clinical presentation, and diagnosis";
var content_f43_29_44502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44502/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44502/contributors\">",
"     M Safwan Badr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44502/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44502/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44502/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44502/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/29/44502/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17199584\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central sleep apnea (CSA) is a disorder characterized by repetitive cessation or decrease of both airflow and ventilatory effort during sleep. It can be primary (ie, idiopathic CSA) or secondary. Examples of secondary CSA include CSA associated with Cheyne-Stokes breathing, a medical condition, a drug or substance, or high altitude periodic breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/1\">",
"     1",
"    </a>",
"    ]. CSA associated with Cheyne-Stokes breathing is particularly common, especially among patients who have heart failure or have had a stroke. It is characterized by central apneas that occur during the decrescendo portion of the cyclic crescendo-decrescendo respiratory pattern. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11301?source=see_link&amp;anchor=H5#H5\">",
"     \"Classification of sleep disorders\", section on 'Sleep related breathing disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CSA can alternatively be categorized as hyperventilation- or hypoventilation-related. Hyperventilation-related CSA encompasses most of the types of CSA mentioned above, with CSA associated with a drug or substance being a notable exception. Hypoventilation-related CSA occurs in disorders in which there is alveolar hypoventilation that is so severe that central apneas occur when the patient falls asleep because the wakefulness stimulus to breathe disappears. Central apneas tend to be a minor component of such disorders. Examples of contexts in which hypoventilation-related CSA may occur include central nervous system diseases, central nervous system suppressing drugs or substances, neuromuscular diseases, and severe abnormalities in pulmonary mechanics (eg, kyphoscoliosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H2#H2\">",
"     \"Central sleep apnea: Pathogenesis\", section on 'Central apnea due to hyperventilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H3#H3\">",
"     \"Central sleep apnea: Pathogenesis\", section on 'Central apnea due to hypoventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation and diagnosis of hyperventilation-related CSA are reviewed here. Hypoventilation-related CSA is not discussed here because central apneas tend to be a minor component of the underlying condition and, therefore, the presentation and diagnosis are dictated by the underlying condition. The pathogenesis and treatment of CSA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link\">",
"     \"Central sleep apnea: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39239?source=see_link\">",
"     \"Central sleep apnea: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of symptomatic CSA (ie, CSA syndrome) appears to be higher among individuals who are elderly, male, or have certain comorbid conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of CSA syndrome is greater among adults who are older than 65 years than among younger adults (1.1 versus 0.4 percent), according to an observational study of 741 randomly selected adults that defined CSA sydrome as a central apnea-hypopnea index &ge;10 events per hour plus symptoms or signs of disrupted sleep (eg, daytime sleepiness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/2\">",
"     2",
"    </a>",
"    ]. The study also found that 12 percent of the adults older than 65 years had &ge;2.5 central apneas per hour of sleep compared with only 1.7 percent of younger adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased prevalence of CSA syndrome among older adults may reflect the higher frequency of comorbid conditions that influence breathing during sleep among older adults, such as heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/3\">",
"     3",
"    </a>",
"    ], atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/4\">",
"     4",
"    </a>",
"    ], and cerebrovascular diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Alternatively, it may be related to sleep state oscillation precipitating central apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H4#H4\">",
"     \"Central sleep apnea: Pathogenesis\", section on 'Central apnea at sleep onset'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSA syndrome is more prevalent among men than women, according to the observational study of 741 adults that was described above. In the study, the prevalence of CSA syndrome was 0.4 percent among men and zero percent among women, while central apneas were detected in 7.8 percent of men and only 0.3 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/8\">",
"     8",
"    </a>",
"    ]. This gender difference was supported by another study, which found a lower apneic threshold among women than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/9\">",
"     9",
"    </a>",
"    ]. The apneic threshold is used as a measure of susceptibility to central apnea. It is the arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) level below which a central apnea is induced. A higher apneic threshold requires the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    to be decreased a smaller amount to induce central apnea. In contrast, a lower apneic threshold requires the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    to be reduced a greater amount to induce central apnea. Thus, a higher apneic threshold is indicative of greater susceptibility to central apnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link\">",
"     \"Central sleep apnea: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The difference between women and men appears to be related to lower testosterone levels among women, as illustrated by the following observations. Administration of testosterone to healthy premenopausal women for 12 days increases the apneic threshold during non-rapid eye movement (NREM) sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/10\">",
"     10",
"    </a>",
"    ]. Conversely, suppression of testosterone with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate in healthy males decreases the apneic threshold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSA associated with Cheyne-Stokes breathing and obstructive sleep apnea (OSA) are prevalent among patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/3,12-14\">",
"     3,12-14",
"    </a>",
"    ]. The former is particularly common among individuals with heart failure who are male, older than 60 years, have atrial fibrillation, or have daytime hypocapnia (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &lt;38 mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/15\">",
"     15",
"    </a>",
"    ]. CSA and OSA in patients with heart failure are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSA is common after a cerebrovascular accident (CVA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. This was illustrated by a prospective cohort study of 161 patients who had a CVA. Approximately 70 percent of patients developed sleep apnea (defined as an apnea-hypopnea index &gt;10 events per hour) within the initial 72 hours, including 26 percent with CSA in the context of Cheyne-Stokes breathing. Three months later, CSA was detected in only 7 percent of the patients, suggesting that CSA following a CVA is often self-limited. There was no relationship between the location of the CVA and the likelihood of sleep apnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSA appears to be common among patients with certain medical conditions, including the use of a long-acting opioid (ie, stable",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/17\">",
"     17",
"    </a>",
"    ], acromegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4409381\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of CSA may be elucidated by a medical history, physical examination, or routine inpatient monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26263960\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CSA typically present with symptoms of disrupted sleep, such as excessive daytime sleepiness, poor subjective sleep quality, insomnia, inattention, and poor concentration. They may also report symptoms due to the recurrent central apneas with oxyhemoglobin desaturation, including paroxysmal nocturnal dyspnea, morning headaches, and nocturnal angina. These may be the presenting complaints, reported during the evaluation of another complaint, or detected during health maintenance screening. Alternatively, CSA may be first suspected when a hospitalized patient is being monitored and is noted to have episodic oxyhemoglobin desaturation, pauses in breathing, or nocturnal arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4409547\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive daytime sleepiness is a common feature of CSA. However, it may go unnoticed or its significance may be underestimated because of its insidious onset and chronicity. Therefore, careful questioning is essential to uncover subtle drowsiness in boring, passive, or monotonous situations, such as driving, watching television, and reading. Excessive daytime sleepiness may not be present and is not a required feature of CSA, as some patients complain of insomnia due to the repetitive awakenings instead.",
"   </p>",
"   <p>",
"    In addition to daytime sleepiness, the clinician should ask about other symptoms of disrupted sleep, such as poor subjective sleep quality, fatigue, inattention, poor concentration, moodiness, decreased libido, and impotence. Patients may complain of paroxysmal nocturnal dyspnea due to the compensatory hyperpnea that follows a central apnea, or they may report morning headaches and nocturnal angina due to the episodic oxyhemoglobin desaturation. Bed partners may report apneic periods.",
"   </p>",
"   <p>",
"    CSA is typically associated with another medical condition and, therefore, patients often report the symptoms of the coexisting condition. As an example, patients with CSA associated with Cheyne-Stokes breathing may report symptoms of heart failure, such as dyspnea on exertion, orthopnea, and paroxysmal nocturnal dyspnea. When the CSA occurs in the context of Cheyne-Stokes breathing, the bed partner may report episodic hyperpnea, hypopnea, and apneic periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4409554\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no physical findings that are specific for CSA. However, patients who have CSA associated with another condition typically have physical findings due to the associated condition. As examples, patients with CSA associated with Cheyne-Stokes breathing due to heart failure frequently have peripheral edema, crackles, an S3 gallop, jugular venous distension, or right upper quadrant pain due to hepatic congestion, while patients with CSA associated with stroke may have asymmetric weakness, sensory or cranial nerve abnormalities, or ataxia. Many patients with CSA have an irregularly irregular pulse due to atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4409758\">",
"    <span class=\"h2\">",
"     Monitoring data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalized patients who are being monitored may exhibit abnormalities due to CSA. Among the more common monitoring abnormalities are episodic apneic periods detected by a respiratory monitor, episodic oxyhemoglobin desaturation detected by continuous pulse oximetry, atrial fibrillation detected by telemetry while the patient is asleep or awake, and nocturnal arrhythmias detected by telemetry. While such monitoring data are not specific enough to confirm or exclude CSA, they warrant consideration of CSA, particularly when risk factors for CSA exist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with daytime sleepiness plus risk factors for CSA (eg, heart failure, stroke, use of a long-acting opioid [eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance]) or more than one symptom or sign of CSA (eg, daytime sleepiness, insomnia, morning headaches, nocturnal angina, witnessed pauses in breathing during sleep) should undergo full-night, attended, in-laboratory polysomnography (PSG). PSG is considered the gold standard diagnostic test for sleep-related breathing disorders. Ambulatory diagnosis and management, including unattended portable monitoring of sleep, have not been validated for the management of central sleep apnea.",
"   </p>",
"   <p>",
"    During PSG, the patient is connected to a variety of monitoring devices. Physiologic variables are recorded digitally on a paperless computerized system while the patient sleeps and during any intervening wakefulness. These include sleep stages (via electroencephalography, electrooculography, submental electromyography), respiratory effort (usually via respiratory inductive plethysmography plus electromyography, strain gauges, piezo electrodes, or impedance devices), airflow (usually via a nasal pressure transducer and oronasal thermistor), oxyhemoglobin saturation (via continuous pulse oximetry), and heart rate and rhythm (via continuous electrocardiography). The sleeping room is usually equipped with an infrared camera and audio system that allows the technologist to see, hear, and communicate with the patient without entering the bedroom. Patterns of physiologic abnormalities during sleep are often diagnostic. PSG is discussed in the context of the evaluation of obstructive sleep apnea separately. However, the much of the discussion is also relevant to patients with potential CSA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4409791\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria for CSA vary according to the type of CSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary CSA requires the following three findings: Polysomnography (PSG) reveals &ge;5 central apneas per hour of sleep; the patient reports excessive daytime sleepiness, awakening with shortness of breath, frequent arousals and awakenings during sleep, or insomnia; and, the disorder is not better explained by another sleep disorder, medical disorder, neurological disorder, medication use, or substance abuse.",
"     </li>",
"     <li>",
"      CSA associated with Cheyne-Stokes breathing requires the following three findings: PSG reveals &ge;10 central apneas or hypopneas per hour of sleep with central apneas occurring during the decrescendo portion of a crescendo-decrescendo respiratory pattern, accompanied by frequent arousals from sleep and derangement of sleep structure; the breathing pattern is associated with a serious medical illness (eg, heart failure, stroke, renal failure); and, the disorder is not better explained by another sleep disorder, medication use, or substance abuse.",
"     </li>",
"     <li>",
"      CSA associated with high altitude periodic breathing requires the following two findings: Recent ascent to an altitude of &ge;4000 meters and PSG reveals &gt;5 central apneas per hour of sleep. The central apneas should occur every 12 to 34 seconds and primarily during non-rapid eye movement (NREM) sleep.",
"     </li>",
"     <li>",
"      CSA associated with a medication or substance requires the following three findings: The patient has been taking a long-acting opioid regularly for at least two months; PSG reveals either &ge;5 central apneas per hour of sleep or &ge;10 central apneas or hypopneas per hour of sleep with central apneas occurring during the decrescendo portion of a crescendo-decrescendo respiratory pattern, with the latter accompanied by frequent arousals from sleep and derangement of sleep structure; and, the disorder is not better explained by another sleep disorder, medical disorder, or neurological disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Central apneas and hypopneas are defined separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4409823\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of conditions must be considered in the differential diagnosis of CSA because they similarly cause excessive daytime sleepiness and other symptoms and signs of disrupted sleep. All of these conditions are distinguished via polysomnography:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive sleep apnea &ndash; Obstructive sleep apnea (OSA) is a disorder that is characterized by repetitive obstructive apneas and hypopneas caused by complete and partial collapse of the upper airway during sleep, respectively. These obstructive events typically lead to awakenings, resulting in symptoms and signs of disrupted sleep. Among the disorders in the differential diagnosis of CSA, OSA is the most closely related because only CSA and OSA are characterized by symptoms and signs of episodic oxyhemoglobin desaturation (eg, morning headaches). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"       \"Management of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Upper airway resistance syndrome &ndash; Upper airway resistance syndrome (UARS) was previously classified as an independent disorder, but it is now considered a type of OSA according to the most recent International Classification of Sleep Disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/1\">",
"       1",
"      </a>",
"      ]. It exists when airflow limitation due to increased upper airway resistance (ie, respiratory effort related arousals [RERAs]) induces arousals from sleep, leading to excessive daytime sleepiness. Patients with UARS have few discrete respiratory disturbances (ie, apneas or hypopneas) or episodes of desaturation. It is common in thin women with certain craniofacial abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H19#H19\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Upper airways resistance syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Periodic limb movements of sleep &ndash; Periodic limb movements of sleep (PLMS) are recurrent jerks of the legs and arms that can fragment sleep, leading to daytime sleepiness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rotating shift workers &ndash; Night-shift workers obtain approximately seven hours per week less sleep than non-shift workers. They often revert to a daytime schedule on their leisure days, which adds to their sleep deprivation and daytime sleepiness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=see_link&amp;anchor=H6#H6\">",
"       \"Types of insomnia\", section on 'Shift work'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Narcolepsy &ndash; Narcolepsy is a clinical syndrome of excess daytime sleepiness with cataplexy, hypnagogic hallucinations, and sleep paralysis. &ldquo;Sleep attacks&rdquo; are classically described, although there is a wide spectrum of clinical presentations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/29/44502/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=see_link\">",
"       \"Clinical features and diagnosis of narcolepsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4071?source=see_link\">",
"       \"Treatment of narcolepsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory disease &ndash; Patients with either chronic obstructive lung disease or restrictive lung disease may have sleep-related hypoventilation with desaturation, resulting in sudden awakenings and dyspnea that imitate CSA. Patients with neuromuscular disease depend on their accessory muscles to breathe and the inhibition of muscle activity during rapid eye movement (REM) sleep can cause hypoventilation with profound desaturations and awakenings. Poorly controlled asthma is often worse at night, with nocturnal bronchospasm and cough inducing sleep fragmentation and paroxysmal dyspnea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central sleep apnea (CSA) is a disorder characterized by repetitive cessation or decrease of both airflow and ventilatory effort during sleep. It can be primary (ie, idiopathic CSA) or secondary. Examples of secondary CSA include CSA associated with Cheyne-Stokes breathing, a medical condition, a drug or substance, or high altitude periodic breathing. (See",
"      <a class=\"local\" href=\"#H17199584\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CSA is uncommon among the general population; however, its prevalence is higher among individuals who are elderly, male, or have certain comorbid conditions, such as heart failure or stroke. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CSA typically present with symptoms of disrupted sleep (eg, excessive daytime sleepiness, poor subjective sleep quality, insomnia, inattention, and poor concentration)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms due to recurrent central apneas with oxyhemoglobin desaturation (eg, paroxysmal nocturnal dyspnea, morning headaches, and nocturnal angina). These may be the presenting complaints, reported during the evaluation of another complaint, or detected during health maintenance screening. Alternatively, CSA may be first suspected when a hospitalized patient is being monitored and is noted to have episodic oxyhemoglobin desaturation, pauses in breathing, or nocturnal arrhythmias. (See",
"      <a class=\"local\" href=\"#H26263960\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with daytime sleepiness plus risk factors for CSA (eg, heart failure, stroke,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance) or more than one symptom or sign of CSA (eg, daytime sleepiness, insomnia, morning headaches, nocturnal angina, witnessed pauses in breathing during sleep) should undergo full-night, attended, in-laboratory polysomnography (PSG). PSG is considered the gold standard diagnostic test for sleep-related breathing disorders. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic criteria for CSA vary according to the type of CSA. Generally speaking, diagnosis generally requires evidence of frequent central apneas via polysomnography, symptoms or signs of disrupted sleep, association with an underlying cause, and exclusion of alternative diagnoses. (See",
"      <a class=\"local\" href=\"#H4409791\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of conditions must be considered in the differential diagnosis of CSA because they similarly cause excessive daytime sleepiness and other symptoms and signs of disrupted sleep. All of these conditions are distinguished by polysomnography. They include obstructive sleep apnea, periodic limb movements of sleep, shift work, narcolepsy, and respiratory disease. (See",
"      <a class=\"local\" href=\"#H4409823\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     The International Classification of Sleep Disorders, 2nd edition, Diagnostic and Coding Manual, 2nd ed, Hauri PJ (Ed), American Academy of Sleep Medicine, Westchester 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/2\">",
"      Bixler EO, Vgontzas AN, Ten Have T, et al. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med 1998; 157:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/3\">",
"      Bradley TD, Floras JS. Sleep apnea and heart failure: Part II: central sleep apnea. Circulation 2003; 107:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/4\">",
"      Leung RS, Huber MA, Rogge T, et al. Association between atrial fibrillation and central sleep apnea. Sleep 2005; 28:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/5\">",
"      Bassetti C, Aldrich MS. Sleep apnea in acute cerebrovascular diseases: final report on 128 patients. Sleep 1999; 22:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/6\">",
"      Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med 2010; 6:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/7\">",
"      Pack AI, Silage DA, Millman RP, et al. Spectral analysis of ventilation in elderly subjects awake and asleep. J Appl Physiol 1988; 64:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/8\">",
"      Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/9\">",
"      Skatrud JB, Dempsey JA. Interaction of sleep state and chemical stimuli in sustaining rhythmic ventilation. J Appl Physiol 1983; 55:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/10\">",
"      Zhou XS, Rowley JA, Demirovic F, et al. Effect of testosterone on the apneic threshold in women during NREM sleep. J Appl Physiol 2003; 94:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/11\">",
"      Mateika JH, Omran Q, Rowley JA, et al. Treatment with leuprolide acetate decreases the threshold of the ventilatory response to carbon dioxide in healthy males. J Physiol 2004; 561:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/12\">",
"      Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 1998; 97:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/13\">",
"      Javaheri S, Parker TJ, Wexler L, et al. Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med 1995; 122:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/14\">",
"      Javaheri S. Central sleep apnea-hypopnea syndrome in heart failure: prevalence, impact, and treatment. Sleep 1996; 19:S229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/15\">",
"      Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999; 160:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/16\">",
"      Bassetti C, Aldrich MS, Chervin RD, Quint D. Sleep apnea in patients with transient ischemic attack and stroke: a prospective study of 59 patients. Neurology 1996; 47:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/17\">",
"      Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest 2005; 128:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/18\">",
"      Grunstein RR, Ho KY, Berthon-Jones M, et al. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am J Respir Crit Care Med 1994; 150:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/19\">",
"      Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991; 115:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/20\">",
"      Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/21\">",
"      Guilleminault C, Stoohs R, Clerk A, et al. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993; 104:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/22\">",
"      Guilleminault C, Stoohs R, Kim YD, et al. Upper airway sleep-disordered breathing in women. Ann Intern Med 1995; 122:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44502/abstract/23\">",
"      Black JE, Brooks SN, Nishino S. Conditions of primary excessive daytime sleepiness. Neurol Clin 2005; 23:1025.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7701 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44502=[""].join("\n");
var outline_f43_29_44502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17199584\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4409381\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26263960\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4409547\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4409554\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4409758\">",
"      Monitoring data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4409791\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4409823\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=related_link\">",
"      Central sleep apnea: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39239?source=related_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11301?source=related_link\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4071?source=related_link\">",
"      Treatment of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_29_44503="Abiraterone: Drug information";
var content_f43_29_44503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Abiraterone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/42/42660?source=see_link\">",
"    see \"Abiraterone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12805570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zytiga&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13203911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zytiga&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10934413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiandrogen;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antiandrogen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10934416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prostate cancer, metastatic, castration-resistant:",
"     </b>",
"     Oral: 1000 mg once daily (in combination with prednisone)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10934417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12805617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12805616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Hepatic impairment",
"     <b>",
"      <i>",
"       prior to",
"      </i>",
"     </b>",
"     treatment initiation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild (Child-Pugh class A): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate (Child-Pugh class B): 250 mg once daily (",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling does not recommend use). Permanently discontinue treatment if ALT and/or AST &gt;5 times the upper limit of normal (ULN) or total bilirubin &gt;3 times ULN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe (Child-Pugh class C): Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Hepatotoxicity",
"     <b>",
"      <i>",
"       during",
"      </i>",
"     </b>",
"     treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     ALT and/or AST &gt;5 times ULN or total bilirubin &gt;3 times ULN: Withhold treatment until liver function tests return to baseline or ALT and AST &le;2.5 times ULN and total bilirubin &le;1.5 times ULN, then reinitiate at 750 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Recurrent hepatotoxicity on 750 mg/day: Withhold treatment until liver function tests return to baseline or ALT and AST &le;2.5 times ULN and total bilirubin &le;1.5 times ULN, then reinitiate at 500 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Recurrent hepatotoxicity on 500 mg/day: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     ALT and/or AST &gt;5 times ULN or total bilirubin &gt;3 times ULN:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Withhold treatment until liver function tests return to baseline, then reinitiate at 500 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Recurrent hepatotoxicity on 500 mg/day: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     ALT &gt;20 times ULN (any time during treatment): Discontinue permanently.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F12805615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatotoxicity: Refer to Dosing: Hepatic Impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12805632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zytiga&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12805571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10934418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally on an empty stomach, at least 1 hour before and 2 hours after food. Swallow tablets whole with water. Do not crush or chew.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12805572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic, castration-resistant prostate cancer (in combination with prednisone)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16141143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zytiga&reg; may be confused with Jevtana&reg;, Xgeva&reg;, Xtandi&reg;, Zometa&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12805581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions reported for use in combination with prednisone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (25% to 27%), hypertension (9% to 22%; grades 3/4: 1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (39%), insomnia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (63%), hyperglycemia (57%), hypernatremia (33%), hypokalemia (17% to 28%; grades 3/4: 3% to 5%), hypophosphatemia (24%; grades 3/4: 7%), hot flush (19% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (23%), diarrhea (18% to 22%), dyspepsia (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphopenia (38%; grades 3/4: 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (11% to 42%; grades 3/4: 1% to 6%), AST increased (31% to 37%; grades 3/4: 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Joint swelling/discomfort (30%), muscle discomfort (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (11% to 17%), upper respiratory infection (5% to 13%), dyspnea (12%), nasopharyngitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Arrhythmia (7%), chest pain/discomfort (4%), heart failure (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Hematuria (10%), polyuria (7%), nocturia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Bilirubin increased (7%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Groin pain (7%), falling (6%), fractures (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Adrenal insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12805577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in women who are or may become pregnant",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindication (not in U.S. labeling): Hypersensitivity to abiraterone acetate or any component of the formulation or container",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12805578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Adrenocortical insufficiency:  Concurrent infection, stress, or interruption of daily corticosteroids is associated with reports of adrenocortical insufficiency. Monitor closely for signs and symptoms of adrenocorticoid insufficiency, which could be masked by adverse events associated with mineralocorticoid excess. Diagnostic testing for adrenal insufficiency may be clinically indicated. Increased corticosteroid doses may be required before, during,  and after stress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Significant increases in liver enzymes have been reported (higher likelihood in patients with baseline elevations), generally occurring in the first 3 months of treatment. May require dosage reduction or discontinuation. ALT, AST, and bilirubin should be monitored prior to treatment, every 2 weeks for 3 months and monthly thereafter; patients with hepatic impairment, elevations in liver function tests, or experiencing hepatotoxicity require more frequent monitoring (see dosage adjustment for hepatic impairment and monitoring parameters). Evaluate liver function promptly with signs or symptoms of hepatotoxicity. The safety of retreatment after significant elevations (ALT or AST &gt;20 times the upper limit of normal [ULN] and/or total bilirubin &gt;10 times ULN) has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Mineralocorticoid excess: Increased mineralocorticoids due to CYP17 inhibition may result in hypertension, hypokalemia, and fluid retention (including grade 3 and 4 events). Concomitant administration with corticosteroids reduces the incidence and severity of these adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: May cause hypertension, hypokalemia, and fluid retention. Use with caution in patients with cardiovascular disease, particularly with heart failure, recent MI, or ventricular arrhythmia. Patients with left ventricular ejection fraction (LVEF) &lt;50% or NYHA class III or IV heart failure were excluded from clinical trials. Monitor at least monthly for hypertension, hypokalemia, and fluid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Avoid use in patients with pre-existing severe hepatic impairment; dosage reduction is recommended in patients with baseline moderate impairment. Canadian labeling (not in U.S. labeling) also recommends avoiding use in patients with pre-existing moderate hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CYP-mediated interactions: Avoid (or use caution) with concomitant CYP3A4 strong inhibitors and inducers. Avoid concurrent administration with CYP2D6 substrates with a narrow therapeutic index (eg, thioridazine); if concurrent administration cannot be avoided, consider a dose reduction of the CYP2D6 substrate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Food: Must be administered on an empty stomach (administer at least 1 hour before and 2 hours after any food).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP2C19 (moderate), CYP2C8 (strong), CYP2C9 (moderate), CYP2D6 (strong), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12817652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: Abiraterone Acetate may increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Strong) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: Abiraterone Acetate may increase the serum concentration of CYP2D6 Substrates.  Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.  Management: Avoid concurrent use of strong CYP2C8 inhibitors and enzalutamide if possible. If the combination must be used, reduce enzalutamide to 80 mg once daily.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.  Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the therapeutic effect of Abiraterone Acetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12805585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Taking with food will increase systemic exposure. Management: Do not administer with food. Must be taken on an empty stomach, at least 1 hour before and 2 hours after food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12805573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12805574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies at doses resulting in less systemic exposure than in humans. Adverse effects were also observed in the reproductive system of animals during toxicology and pharmacology studies. Based on the mechanism of action, abiraterone may cause fetal harm or fetal loss if administered during pregnancy. Abiraterone is not indicated for use in women and is specifically contraindicated in women who are or may become pregnant. It is not known if abiraterone is excreted in semen, therefore, men should use a condom and another method of birth control during treatment and for 1 week following therapy if having intercourse with a woman of reproductive age. Women who are or may become pregnant should wear gloves if contact with tablets may occur.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12805575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12805576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in women",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F12805622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be taken on an empty stomach, at least 1 hour before and 2 hours after food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zytiga Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (120): $7674.37",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12805623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ALT, AST, and bilirubin prior to treatment, every 2 weeks for 3 months and monthly thereafter; if baseline moderate hepatic impairment (Child-Pugh class B), monitor ALT, AST, and bilirubin prior to treatment, weekly for the first month, every 2 weeks for 2 months then monthly thereafter. If hepatotoxicity develops during treatment (and only after therapy is interrupted and liver function tests have returned to safe levels), monitor ALT, AST, and bilirubin every 2 weeks for 3 months and monthly thereafter. Monitoring of testosterone levels is not necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Monitor for signs and symptoms of adrenocorticoid insufficiency; if clinically indicated, consider appropriate diagnostics to confirm adrenal insufficiency.  Monitor monthly for hypertension, hypokalemia, and fluid retention.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zytiga (AU, BE, CH, CZ, DE, DK, EE, FR, GB, IE, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12805588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively and irreversibly inhibits CYP17 (17 alpha-hydroxylase/C17,20-lyase), an enzyme required for androgen biosynthesis which is expressed in testicular, adrenal, and prostatic tumor tissues. Inhibits the formation of the testosterone precursors dehydroepiandrosterone (DHEA) and androstenedione.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12805591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 19,669 &plusmn; 13,358 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99%; to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Abiraterone acetate is hydrolyzed to the active metabolite abiraterone; further metabolized to inactive metabolites abiraterone sulphate and N-oxide abiraterone sulphate via CYP3A4 and SULT2A1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Systemic exposure is increased by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 14.4-16.5 hours (Acharya, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 2 hours (Acharya, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~88%); urine (~5%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Acharya M, Bernard A, Gonzalez M, et al, &ldquo;Open-Label, Phase I, Pharmacokinetic Studies of Abiraterone Acetate in Healthy Men,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2012, 69(6):1583-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44503/abstract-text/22526411/pubmed\" id=\"22526411\" target=\"_blank\">",
"        22526411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Attard G, Reid AH, A&rsquo;Hern R, et al, &ldquo;Selective Inhibition of CYP17 With Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(23):3742-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44503/abstract-text/19470933/pubmed\" id=\"19470933\" target=\"_blank\">",
"        19470933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Danila DC, Morris MJ, de Bono JS, et al, &ldquo;Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(9):1496-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44503/abstract-text/20159814/pubmed\" id=\"20159814\" target=\"_blank\">",
"        20159814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Bono JS, Logothetis CJ, Molina A, et al, &ldquo;Abiraterone and Increased Survival in Metastatic Prostate Cancer,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2011, 364(21):1995-2005.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fizazi K, Scher HI, Molina A, et al, &ldquo;Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(10):983-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44503/abstract-text/22995653/pubmed\" id=\"22995653\" target=\"_blank\">",
"        22995653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reid AH, Attard G, Danila DC, et al, &ldquo;Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(9):1489-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44503/abstract-text/20159823/pubmed\" id=\"20159823\" target=\"_blank\">",
"        20159823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ryan CJ, Shah S, Efstathiou E, et al, &ldquo;Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant With Serologic Response,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2011, 17(14):4854-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44503/abstract-text/21632851/pubmed\" id=\"21632851\" target=\"_blank\">",
"        21632851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ryan CJ, Smith MR, de Bono JS, et al, &ldquo;Interim Analysis (IA) Results of COU-AA-302, a Randomized, Phase III Study of Abiraterone Acetate (AA) in Chemotherapy-Naive Patients (Pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(18s): LBA4518 [abstract LBA4518 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ryan CJ, Smith MR, Fong L, et al, &ldquo;Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol,",
"      </i>",
"      2010, 28(9):1481-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44503/abstract-text/20159824/pubmed\" id=\"20159824\" target=\"_blank\">",
"        20159824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tolcher AW, Chi KN, Shore ND, et al, &ldquo;Effect of Abiraterone Acetate Plus Prednisone on the QT Interval In Patients With Metastatic Castration-Resistant Prostate Cancer,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2012, 70(2):305-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/29/44503/abstract-text/22752297/pubmed\" id=\"22752297\" target=\"_blank\">",
"        22752297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16083 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44503=[""].join("\n");
var outline_f43_29_44503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203911\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10934413\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10934416\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10934417\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805617\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805616\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805615\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805632\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805571\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10934418\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805572\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16141143\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805581\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805577\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805578\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298629\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817652\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805585\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805573\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805574\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805575\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805576\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805622\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322870\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805623\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733202\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805588\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805591\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16083\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16083|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/42/42660?source=related_link\">",
"      Abiraterone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_29_44504="Predicting the severity of acute pancreatitis";
var content_f43_29_44504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Predicting the severity of acute pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44504/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44504/contributors\">",
"     Santhi Swaroop Vege, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44504/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44504/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44504/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44504/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/29/44504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 25 percent of all patients with acute pancreatitis (AP) develop severe AP. Between 1988 and 2003, mortality from acute pancreatitis decreased from 12 percent to 2 percent, according to a large epidemiologic study from the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/1\">",
"     1",
"    </a>",
"    ]. However, mortality rates remain much higher in subgroups of patients with severe disease. The ability to predict its severity can help identify patients at increased risk for morbidity and mortality, thereby assisting in appropriate early triage to intensive care units and selection of patients for specific interventions.",
"   </p>",
"   <p>",
"    This topic review will summarize methods for predicting the severity of AP. The clinical manifestations, diagnosis, and treatment of AP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13832850\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multitude of predictive models have been developed to predict the severity of acute pancreatitis (AP) based upon clinical, laboratory, and radiologic risk factors, various severity grading systems, and serum markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/2\">",
"     2",
"    </a>",
"    ]. Some of these can be performed on admission to assist in triage of patients, while others can only be obtained after the first 48 to 72 hours or later.",
"   </p>",
"   <p>",
"    However, these predictive models have low specificity (ie, high false positive rates), which when coupled with the low prevalence of severe AP (15 to 25 percent) results in low positive predictive values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/3\">",
"     3",
"    </a>",
"    ]. Future predictive models will need to incorporate additional factors (eg, biomarkers, genetic polymorphisms and mutations, and proteomic and metabolomic patterns) and methods of analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ACUTE PANCREATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The revised Atlanta classification system divides acute pancreatitis into two broad categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interstitial edematous acute pancreatitis, which is characterized by acute inflammation of the pancreatic parenchyma and peripancreatic tissues, but without recognizable tissue necrosis",
"     </li>",
"     <li>",
"      Necrotizing acute pancreatitis, which is characterized by inflammation associated with pancreatic parenchymal necrosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peripancreatic necrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to the severity, acute pancreatitis is divided into the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild acute pancreatitis which is characterized by the absence of organ failure and local or systemic complications",
"     </li>",
"     <li>",
"      Moderately severe acute pancreatitis which is characterized by transient organ failure (resolves within 48 hours)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      local or systemic complications without persistent organ failure (&gt;48 hours)",
"     </li>",
"     <li>",
"      Severe acute pancreatitis which is characterized by persistent organ failure that may involve one or multiple organs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local complications of acute pancreatitis include acute peripancreatic fluid collection, pancreatic pseudocyst, acute necrotic collection, and walled-off necrosis.",
"   </p>",
"   <p>",
"    Organ failure is defined as a score of 2 or more for any one of three organ systems (respiratory, cardiovascular, or renal) using the modified Marshall scoring system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PREDICTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical judgment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical judgment based upon clinical and laboratory data at admission might underestimate the severity of acute pancreatitis (AP). In one review, the clinical judgment of experienced physicians at admission had a sensitivity, specificity, positive predictive value, and negative predictive value of 39, 93, 66, and 82 percent, respectively, for predicting severe AP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Older age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have concluded that older age is a predictor of a worse prognosis, although the age cutoff has varied from 55 to 75 years in different reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In an illustrative study, patients older than 75 years had more than a 15-fold greater chance of dying within two weeks and a more than 22-fold greater chance of dying within 91 days compared with patients aged 35 years or younger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's sex has not been a predictor of outcome in most reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alcoholic pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol as a cause of pancreatitis has been associated with an increased risk of pancreatic necrosis and need for intubation in some reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Short time interval to symptom onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;A time interval between the onset of symptoms and hospital admission of less than 24 hours, as well as rebound tenderness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    guarding were associated with increasing severity of pancreatitis in at least one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have found obesity (defined as a body mass index &gt;30) to be a risk factor for severe AP. A meta-analysis that included 739 patients made the following estimates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe acute pancreatitis, odds ratio (OR) 2.9 (95% CI 1.8-4.6)",
"     </li>",
"     <li>",
"      Systemic complications, OR 2.3 (95% CI 1.4-3.8)",
"     </li>",
"     <li>",
"      Local complications, OR 3.8 (95% CI 2.4-6.6)",
"     </li>",
"     <li>",
"      Mortality, OR 2.1 (95% CI 1.0-4.8)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Organ failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early and persistent organ failure is a reliable indicator of a prolonged hospital stay and increased mortality. In one report, organ failure within 72 hours of admission was associated with the presence of extended pancreatic necrosis and a mortality rate of 42 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/15\">",
"     15",
"    </a>",
"    ]. Several subsequent studies found that the evolution and clinical course of organ failure was a more accurate predictor of adverse outcomes. In one study, persistent and deteriorating (&ge;48 hours) organ failure were associated with mortality rates of 21 and 55 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/16\">",
"     16",
"    </a>",
"    ]. On the other hand, early organ dysfunction that was not persistent (&lt;48 hours) was associated with a mortality rate of 0 percent. In a second study, transient organ failure was associated with a mortality rate of 1.4 percent, whereas persistent organ failure had a 35 percent mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/17\">",
"     17",
"    </a>",
"    ]. Persistent organ failure is widely accepted as a reliable criterion for severe AP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LABORATORY AND RADIOLOGIC PREDICTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hemoconcentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pancreatitis (AP) results in significant third space losses, resulting in hemoconcentration and a high hematocrit. Studies evaluating the hematocrit as a predictor of the severity of AP have produced variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. The discrepancies may be due to differences in values chosen as a cutoff and the time that they were obtained. Despite these differences, it appears that a normal or low hematocrit at admission and during the first 24 hours is generally associated with a milder clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;C-reactive protein (CRP) is one of the acute phase reactants made by the liver in response to interleukin-1 and interleukin-6. Levels of CRP above 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at 48 hours discriminate severe from mild disease. At 48 hours, CRP above 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    has a sensitivity, specificity, positive predictive value, and negative predictive value of 80, 76, 67, and 86 percent, respectively, for severe acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRP rises steadily in relation to the severity of pancreatitis, is inexpensive to measure, and testing is readily available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. As a result, we suggest it be used to help predict the severity of pancreatitis, especially at 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13833085\">",
"    <span class=\"h2\">",
"     Blood urea nitrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a large hospital-based cohort, serial blood urea nitrogen (BUN) measurements were the most reliable routine laboratory test to predict the mortality in AP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/26\">",
"     26",
"    </a>",
"    ]. For every increase in the BUN of 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    during the first 24 hours, the adjusted odds ratio for mortality was 2.2.",
"   </p>",
"   <p>",
"    A subsequent study by the same group that included 1043 patients found that a BUN level of 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or higher at admission was associated with an increased risk of death compared with a BUN level of less than 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (OR 4.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, any increase in BUN at 24 hours was also associated with an increased risk of death (OR 4.3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13833093\">",
"    <span class=\"h2\">",
"     Serum creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated serum creatinine within the first 48 hours may predict the development of pancreatic necrosis. In one study of 129 patients, a peak creatinine of greater than 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    during the first 48 hours had a positive predictive value of 93 percent for the development of pancreatic necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/22\">",
"     22",
"    </a>",
"    ]. However, a study from Germany did not find this association, though it did show that a normal creatinine had a high negative predictive value for the development of pancreatic necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/28\">",
"     28",
"    </a>",
"    ]. The authors suggested that a normal creatinine in the absence of complications obviated the need for an abdominal computed tomographic (CT) scan. The discrepancy between the two studies may have been due to a lower prevalence of pancreatic necrosis in the German study, which could have resulted in a lower positive predictive value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other serum markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other serum markers have been studied for predicting the severity pancreatitis including: urinary trypsinogen activation peptide (TAP), procalcitonin, polymorphonuclear elastase, pancreatic-associated protein, amylase, lipase, serum glucose, serum calcium, procarboxypeptidase-B, carboxypeptidase B activation peptide, serum trypsinogen-2, phospholipase A-2, serum amyloid protein-A, substance P, antithrombin III, platelet activating factor, interleukins 1, 6, and 8, tumor necrosis factor-alpha or soluble tumor necrosis factor receptor, and various genetic polymorphisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/22,29-31\">",
"     22,29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tests for most of these markers are not widely available and their test characteristics are incompletely understood. Exceptions are a dipstick test for procalcitonin, an ELISA test for urine TAP, and a test for urine anionic trypsinogen, which are likely to become commercially available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procalcitonin is the most rapid general acute-phase reactant. In a validation study, the procalcitonin strip test had an accuracy of 86 percent for predicting severe AP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TAP is cleaved from the amino-terminal end of trypsinogen when trypsin is activated. TAP is the most studied activation peptide in AP. A European multicenter study found a sensitivity of 58 percent and specificity of 73 percent with urinary TAP within 24 hours of symptom onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4314399\">",
"    <span class=\"h2\">",
"     Chest radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pleural effusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary infiltrates during the first 24 hours may be associated with necrosis and organ failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3192492\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scan is probably the most frequently used radiologic investigation when severe AP is suspected. It is used to look for pancreatic necrosis and extrapancreatic inflammation. Intravenous contrast-enhanced CT distinguishes between edematous and necrotizing pancreatitis, since areas of necrosis and exudates do not enhance. CT is more accurate than ultrasonography for the diagnosis of severe pancreatic necrosis (90 versus 73 percent in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After assessment of the patient, a contrast-enhanced CT scan is indicated in patients who are deteriorating or have severe pancreatitis determined clinically and by APACHE II score (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?3/8/3205?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). A CT scan is not required on the first day unless there are other diagnoses are being considered. A retrospective analysis of the performance of several CT scoring systems for the severity of acute pancreatitis found that none was statistically superior to the APACHE II or BISAP scoring systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, it takes time for pancreatic necrosis to develop, and treatment is unlikely to be altered on the basis of CT findings on day one. Although there are some experimental data that suggest ionic contrast may worsen pancreatitis, the association is probably not strong and the information obtained from the CT scan justifies the potential risk.",
"   </p>",
"   <p>",
"    Perfusion CT can differentiate reversible from irreversible ischemic tissue in the brain and uses less contrast than the conventional contrast-enhanced CT. One report described the utility of perfusion CT in predicting pancreatic necrosis in early stages of AP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/36\">",
"     36",
"    </a>",
"    ]. Ten of 30 patients with AP had pancreatic ischemia on perfusion CT and nine patients were proven to have pancreatic necrosis subsequently on contrast-enhanced CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3192392\">",
"    <span class=\"h2\">",
"     MRI and MRCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) are being used increasingly to diagnose AP and to assess its severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/37\">",
"     37",
"    </a>",
"    ]. MRI appears to be comparable to CT, if not better, in providing precise information regarding the severity of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. MRI is as effective as CT in demonstrating the presence and extent of pancreatic necrosis and fluid collections, and is probably superior for indicating the suitability of such collections for nonsurgical drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI can characterize the \"pancreatic necrosis\" seen on CT as necrotic pancreatic parenchyma, peripancreatic necrotic fluid collections, or hemorrhagic foci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/40\">",
"     40",
"    </a>",
"    ]. One study found that MRI was reliable for staging the severity of AP and predicting prognosis with fewer contraindications than CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/41\">",
"     41",
"    </a>",
"    ]. It can also detect pancreatic duct disruption, which can occur early in the course of AP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SCORING SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many scoring systems have been reported but none has proven to be perfect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/42\">",
"     42",
"    </a>",
"    ]. While they can be useful to group patients for the purpose of inter-institutional comparisons and reporting, none has high accuracy in predicting the severity of acute pancreatitis (AP) in a given patient at the bedside. On the other hand, they are superior to clinical judgment for triaging patients to more intensive care and aggressive therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical judgment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many scoring systems (eg, Ranson, Glasgow) take 48 hours to complete, can be used only once, and do not have a high degree of sensitivity and specificity (",
"    <a class=\"graphic graphic_table graphicRef56775 \" href=\"mobipreview.htm?37/5/37979\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. In addition, some have limited utility since they focus on specific complications (eg, Banks) or are invasive (eg, Leeds diagnostic peritoneal lavage) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/43\">",
"     43",
"    </a>",
"    ]. As a result, many of these systems are not used routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ranson's criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A score based upon Ranson's criteria is one of the earliest scoring systems for severity in AP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/44\">",
"     44",
"    </a>",
"    ]. Ranson's criteria consist of 11 parameters. Five of the factors are assessed at admission and six are assessed during the next 48 hours (",
"    <a class=\"graphic graphic_table graphicRef56775 \" href=\"mobipreview.htm?37/5/37979\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?7/16/7425?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). A later modification for biliary pancreatitis included only 10 points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/46\">",
"     46",
"    </a>",
"    ]. Mortality increases with an increasing score. Using the 11 component score, mortality was 0 to 3 percent when the score was &lt;3, 11 to 15 percent when the score was &ge;3, and 40 percent when the score was &ge;6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the system continues to be used, a meta-analysis of 110 studies found the Ranson score to be a poor predictor of severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     The APACHE II score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute physiology and chronic health examination (APACHE) II score was originally developed for critically ill patients in intensive care units. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=see_link\">",
"     \"Predictive scoring systems in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has 12 physiologic measures and extra points based upon age and presence of chronic disease (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?3/8/3205?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). It is probably the most widely studied severity scoring system in AP. It has good negative predictive value and modest positive predictive value for predicting severe AP and can be performed daily. Decreasing values during the first 48 hours suggest a mild attack, while increasing values suggest a severe attack. Studies suggest that mortality is less than 4 percent with a score &lt;8 and is 11 to 18 percent with a score &gt;8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some limitations of the APACHE II score are that is complex and cumbersome to use, it does not differentiate between interstitial and necrotizing pancreatitis, and it does not differentiate between sterile and infected necrosis. Finally, it has a poor predictive value at 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of a body mass index (BMI) score to APACHE II (known as APACHE O) improved the prediction of severe pancreatitis compared with the conventional APACHE II score in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/48\">",
"     48",
"    </a>",
"    ]. One point was added for a BMI of &gt;25 to 30 and two points were added for a BMI &gt;30. However, the improved performance of APACHE O was not validated in a second study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/49\">",
"     49",
"    </a>",
"    ]. A simplified Acute Physiology Score II developed in ICU patients may be comparable to APACHE II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=see_link\">",
"     \"Predictive scoring systems in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several additional variables were added to APACHE II to improve its accuracy leading to the development of APACHE III. Both APACHE II and III scores use physiology, age, and chronic health to calculate prognosis; they differ in total score, the number of physiologic variables (12 for APACHE II versus 17 for APACHE III), and the assessment of chronic health status. However, the APACHE III system does not appear to be as useful as APACHE II for distinguishing mild from severe attack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Systemic inflammatory response syndrome score",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the presence of the systemic inflammatory response syndrome (SIRS) is associated with increased mortality. A score based upon the systemic inflammatory response syndrome has been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/52\">",
"     52",
"    </a>",
"    ]. Initial studies suggest it can reliably predict the severity of pancreatitis and has the added advantage that it can be applied easily at the bedside every day (",
"    <a class=\"graphic graphic_table graphicRef69207 \" href=\"mobipreview.htm?3/25/3483\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/16\">",
"     16",
"    </a>",
"    ]. In one validation study, mortality rates were 25, 8, and 0 percent in those with persistent SIRS from admission, SIRS at admission but not persistent, and no SIRS, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/53\">",
"     53",
"    </a>",
"    ]. Another study found that the severity of AP was greater among patients with AP and SIRS on day one, particularly in those with three or four SIRS criteria, compared with those without SIRS on day one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, it appears that the SIRS score is inexpensive, readily available, and compares favorably with other more complicated scores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     BISAP score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of the bedside index of severity in acute pancreatitis (BISAP) score was based upon 17,922 cases of AP from 2000 to 2001 and validated in 18,256 cases from 2004 to 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients are assigned 1 point for each of the following during the first 24 hours: BUN &gt;25",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    impaired mental status, SIRS (using the same criteria as the SIRS score, (",
"    <a class=\"graphic graphic_table graphicRef69207 \" href=\"mobipreview.htm?3/25/3483\">",
"     table 2",
"    </a>",
"    )), age &gt;60 years, or the presence of a pleural effusion (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?36/25/37264?source=see_link\">",
"     calculator 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients with a score of zero had a mortality of less than one percent, whereas patients with a score of five had a mortality rate of 22 percent. In the validation cohort, the BISAP score had similar test performance characteristics for predicting mortality as the APACHE II score. As is a problem with many of the other scoring systems, the BISAP has not been validated for predicting outcomes such as length of hospital stay, need for ICU care, or need for intervention.",
"   </p>",
"   <p>",
"    A validation study of the BISAP score that included 185 patients found that its performance was similar to APACHE II, Ranson's criteria, and the CT severity index system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/56\">",
"     56",
"    </a>",
"    ]. While the BISAP score is meant to be easily calculated at the bedside, it has been noted that to do so is not as simple as was initially reported because four variables need to be considered to determine if SIRS is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13833427\">",
"    <span class=\"h2\">",
"     Harmless acute pancreatitis score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The harmless acute pancreatitis score can typically be calculated within 30 minutes of admission and takes into account three parameters: lack of rebound tenderness or guarding, normal hematocrit, and normal serum creatinine. It was derived on a cohort of 394 patients and validated in a cohort of 452 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/58\">",
"     58",
"    </a>",
"    ]. This score correctly identified 200 of 204 patients (98 percent) with a harmless course. Presumably patients were considered likely to have a harmless course if none of the three parameters were present, though this was not clearly defined in the report.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Organ failure-based scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, organ failure is a marker of the severity of pancreatitis. While there are several scoring systems for organ failure, they do not directly measure the severity of AP, but rather measure the severity of the organ failure itself. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Organ failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This distinction is potentially important as reflected in the limitations of Atlanta classification system described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Organ failure was listed as being present or absent, without specifying the number of organs failing or the severity of each organ failure, issues that are potentially clinically relevant. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification of acute pancreatitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Organ failure scoring systems such as the Goris multiple organ failure score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/61\">",
"     61",
"    </a>",
"    ], the Marshall (or multiple) organ dysfunction score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/7\">",
"     7",
"    </a>",
"    ], the Bernard score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/62\">",
"     62",
"    </a>",
"    ], the sequential organ failure assessment (SOFA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/63\">",
"     63",
"    </a>",
"    ], and the logistic organ dysfunction system score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/64\">",
"     64",
"    </a>",
"    ] have been described. All these scores take into account the number of organ systems involved and the degree of dysfunction of each individual organ. Some also include the use of inotropic or vasopressor agents, mechanical ventilation, or dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/7\">",
"     7",
"    </a>",
"    ]. As noted above, the presence of persistent organ failure lasting for more than 48 hours appears to be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Organ failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CT severity index",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CT severity score (the Balthazar score) has been developed based upon the degree of necrosis, inflammation, and the presence of fluid collections (",
"    <a class=\"graphic graphic_table graphicRef68191 \" href=\"mobipreview.htm?12/41/12956\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/65\">",
"     65",
"    </a>",
"    ]. In an initial validation study, mortality was 23 percent with any degree of pancreatic necrosis and 0 percent with no necrosis. In addition, there was a strong association between necrosis &gt;30 percent and morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of necrotizing pancreatitis (or even infected necrosis) does not necessarily predict the occurrence of organ failure, but may alter the therapeutic approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/66\">",
"     66",
"    </a>",
"    ]. In a retrospective study of 268 patients with AP assessed by the CT severity index, patients with a CT severity index &gt;5 were eight times more likely to die, 17 times more likely to have a prolonged hospital course, and 10 times more likely to undergo necrosectomy than the patients with scores &lt;5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/67\">",
"     67",
"    </a>",
"    ]. While necrosis on CT predicts a severe attack, there was no uniform correlation with the extent of necrosis and organ failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality. Such a correlation may become more apparent with newer scoring systems that measure the number of failing organ systems and the severity of each failing organ system. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Organ failure-based scores'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     AGA GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Gastroenterological Association (AGA) has issued guidelines for assessing the severity of pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44504/abstract/29\">",
"     29",
"    </a>",
"    ]. The AGA recommends:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prediction of severe disease be performed using the APACHE II system (using a cutoff of &ge;8) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?3/8/3205?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Those with actual or predicted severe disease and those with other severe comorbid conditions should be considered for triage to an intensive care or intermediate medical care unit.",
"     </li>",
"     <li>",
"      In patients with predicted severe disease (ie, APACHE II score of &ge;8) and those with evidence of organ failure during the initial 72 hours, rapid-bolus CT should be performed after 72 hours of illness to assess the degree of pancreatic necrosis. CT should be used selectively based upon clinical features in patients who do not meet these criteria.",
"     </li>",
"     <li>",
"      Laboratory tests can be used as an adjunct to clinical judgment and the APACHE II score. A serum C-reactive protein level of &gt;150",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      at 48 hours is preferred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/36/41537?source=see_link\">",
"       \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the initial 24 hours, severe acute pancreatitis can be predicted using clinical, laboratory, and radiologic risk factors, many of which have been incorporated into scoring systems such as the SIRS score, the APACHE II score, the BISAP score, and the CT severity index. We favor the SIRS score because it is simple, cheap, readily available, and as accurate as any other complex scoring system, especially persistent SIRS. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Scoring systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a contrast-enhanced CT be performed in patients considered to have severe AP based upon clinical criteria or possibly the APACHE II score (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?3/8/3205?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) to determine if necrotizing pancreatitis is present.",
"      <br/>",
"      <br/>",
"      A CT scan is not required on the first day unless other diagnoses are being considered. It takes time for pancreatic necrosis to develop, and thus CT may be normal in the first 48 hours. As noted above, a guideline issued by the American Gastroenterological Association suggests a CT be performed after 72 hours of illness in patients with predicted severe disease and those with evidence of organ failure during the initial 72 hours. Although there are some experimental data that ionic contrast may worsen pancreatitis, the association is probably not strong, and the information obtained from the CT scan justifies the potential risk. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'AGA guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRI is emerging as a useful imaging tool in pancreatitis, especially to distinguish the contents of fluid collections seen on CT. However, experience remains inadequate in the setting of acute pancreatitis primarily because of its high cost and need for prolonged examination time. (See",
"      <a class=\"local\" href=\"#H3192392\">",
"       'MRI and MRCP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tests have an adjunctive role in predicting the severity of acute pancreatitis. We agree with the guideline issued by the AGA, which suggests that of the available tests, a C-reactive protein level of &gt;150",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      at 48 hours after disease onset is preferred for discriminating patients with severe disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory and radiologic predictors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'AGA guidelines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/1\">",
"      Fagenholz PJ, Castillo CF, Harris NS, et al. Increasing United States hospital admissions for acute pancreatitis, 1988-2003. Ann Epidemiol 2007; 17:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/2\">",
"      Windsor JA. Search for prognostic markers for acute pancreatitis. Lancet 2000; 355:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/3\">",
"      Robert JH, Frossard JL, Mermillod B, et al. Early prediction of acute pancreatitis: prospective study comparing computed tomography scans, Ranson, Glascow, Acute Physiology and Chronic Health Evaluation II scores, and various serum markers. World J Surg 2002; 26:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/4\">",
"      Chauhan S, Forsmark CE. The difficulty in predicting outcome in acute pancreatitis. Am J Gastroenterol 2010; 105:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/5\">",
"      Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993; 128:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/6\">",
"      Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/7\">",
"      Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638.",
"     </a>",
"    </li>",
"    <li>",
"     Larvin M. Assessment of clinical severity and prognosis. In: The Pancreas, Beger HG, Warshaw AL, Buchler MW, et al (Eds), Blackwell Science, Oxford 1998. p.489.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/9\">",
"      Banks PA, Freeman ML, Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 101:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/10\">",
"      Frey CF, Zhou H, Harvey DJ, White RH. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006; 33:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/11\">",
"      Papachristou GI, Papachristou DJ, Morinville VD, et al. Chronic alcohol consumption is a major risk factor for pancreatic necrosis in acute pancreatitis. Am J Gastroenterol 2006; 101:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/12\">",
"      Lankisch PG, Assmus C, Pflichthofer D, et al. Which etiology causes the most severe acute pancreatitis? Int J Pancreatol 1999; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/13\">",
"      Lankisch PG, Blum T, Maisonneuve P, Lowenfels AB. Severe acute pancreatitis: when to be concerned? Pancreatology 2003; 3:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/14\">",
"      Mart&iacute;nez J, Johnson CD, S&aacute;nchez-Pay&aacute; J, et al. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. Pancreatology 2006; 6:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/15\">",
"      Isenmann R, Rau B, Beger HG. Early severe acute pancreatitis: characteristics of a new subgroup. Pancreas 2001; 22:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/16\">",
"      Buter A, Imrie CW, Carter CR, et al. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg 2002; 89:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/17\">",
"      Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut 2004; 53:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/18\">",
"      Brown A, Orav J, Banks PA. Hemoconcentration is an early marker for organ failure and necrotizing pancreatitis. Pancreas 2000; 20:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/19\">",
"      Lankisch PG, Mahlke R, Blum T, et al. Hemoconcentration: an early marker of severe and/or necrotizing pancreatitis? A critical appraisal. Am J Gastroenterol 2001; 96:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/20\">",
"      Baillargeon JD, Orav J, Ramagopal V, et al. Hemoconcentration as an early risk factor for necrotizing pancreatitis. Am J Gastroenterol 1998; 93:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/21\">",
"      Remes-Troche JM, Duarte-Rojo A, Morales G, Robles-D&iacute;az G. Hemoconcentration is a poor predictor of severity in acute pancreatitis. World J Gastroenterol 2005; 11:7018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/22\">",
"      Muddana V, Whitcomb DC, Khalid A, et al. Elevated serum creatinine as a marker of pancreatic necrosis in acute pancreatitis. Am J Gastroenterol 2009; 104:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/23\">",
"      B&uuml;chler M, Malfertheiner P, Schoetensack C, et al. Sensitivity of antiproteases, complement factors and C-reactive protein in detecting pancreatic necrosis. Results of a prospective clinical study. Int J Pancreatol 1986; 1:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/24\">",
"      Wilson C, Heads A, Shenkin A, Imrie CW. C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg 1989; 76:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/25\">",
"      Leese T, Shaw D, Holliday M. Prognostic markers in acute pancreatitis: can pancreatic necrosis be predicted? Ann R Coll Surg Engl 1988; 70:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/26\">",
"      Wu BU, Johannes RS, Sun X, et al. Early changes in blood urea nitrogen predict mortality in acute pancreatitis. Gastroenterology 2009; 137:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/27\">",
"      Wu BU, Bakker OJ, Papachristou GI, et al. Blood urea nitrogen in the early assessment of acute pancreatitis: an international validation study. Arch Intern Med 2011; 171:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/28\">",
"      Lankisch PG, Weber-Dany B, Maisonneuve P, Lowenfels AB. High serum creatinine in acute pancreatitis: a marker for pancreatic necrosis? Am J Gastroenterol 2010; 105:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/29\">",
"      Forsmark CE, Baillie J, AGA Institute Clinical Practice and Economics Committee, AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis. Gastroenterology 2007; 132:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/30\">",
"      Papachristou GI, Whitcomb DC. Predictors of severity and necrosis in acute pancreatitis. Gastroenterol Clin North Am 2004; 33:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/31\">",
"      Blum T, Maisonneuve P, Lowenfels AB, Lankisch PG. Fatal outcome in acute pancreatitis: its occurrence and early prediction. Pancreatology 2001; 1:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/32\">",
"      Kyl&auml;np&auml;&auml;-B&auml;ck ML, Takala A, Kemppainen E, et al. Procalcitonin strip test in the early detection of severe acute pancreatitis. Br J Surg 2001; 88:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/33\">",
"      Talamini G, Uomo G, Pezzilli R, et al. Serum creatinine and chest radiographs in the early assessment of acute pancreatitis. Am J Surg 1999; 177:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/34\">",
"      Block S, Maier W, Bittner R, et al. Identification of pancreas necrosis in severe acute pancreatitis: imaging procedures versus clinical staging. Gut 1986; 27:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/35\">",
"      Bollen TL, Singh VK, Maurer R, et al. A comparative evaluation of radiologic and clinical scoring systems in the early prediction of severity in acute pancreatitis. Am J Gastroenterol 2012; 107:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/36\">",
"      Tsuji Y, Yamamoto H, Yazumi S, et al. Perfusion computerized tomography can predict pancreatic necrosis in early stages of severe acute pancreatitis. Clin Gastroenterol Hepatol 2007; 5:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/37\">",
"      Merkle EM, G&ouml;rich J. Imaging of acute pancreatitis. Eur Radiol 2002; 12:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/38\">",
"      Lecesne R, Taourel P, Bret PM, et al. Acute pancreatitis: interobserver agreement and correlation of CT and MR cholangiopancreatography with outcome. Radiology 1999; 211:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/39\">",
"      Morgan DE, Baron TH, Smith JK, et al. Pancreatic fluid collections prior to intervention: evaluation with MR imaging compared with CT and US. Radiology 1997; 203:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/40\">",
"      Hirota M, Kimura Y, Ishiko T, et al. Visualization of the heterogeneous internal structure of so-called \"pancreatic necrosis\" by magnetic resonance imaging in acute necrotizing pancreatitis. Pancreas 2002; 25:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/41\">",
"      Arvanitakis M, Delhaye M, De Maertelaere V, et al. Computed tomography and magnetic resonance imaging in the assessment of acute pancreatitis. Gastroenterology 2004; 126:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/42\">",
"      Mounzer R, Langmead CJ, Wu BU, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. Gastroenterology 2012; 142:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/43\">",
"      Corfield AP, Cooper MJ, Williamson RC, et al. Prediction of severity in acute pancreatitis: prospective comparison of three prognostic indices. Lancet 1985; 2:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/44\">",
"      Ranson JH, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 1974; 139:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/45\">",
"      Agarwal N, Pitchumoni CS. Simplified prognostic criteria in acute pancreatitis. Pancreas 1986; 1:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/46\">",
"      Ranson JH. The timing of biliary surgery in acute pancreatitis. Ann Surg 1979; 189:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/47\">",
"      De Bernardinis M, Violi V, Roncoroni L, et al. Discriminant power and information content of Ranson's prognostic signs in acute pancreatitis: a meta-analytic study. Crit Care Med 1999; 27:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/48\">",
"      Johnson CD, Toh SK, Campbell MJ. Combination of APACHE-II score and an obesity score (APACHE-O) for the prediction of severe acute pancreatitis. Pancreatology 2004; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/49\">",
"      Papachristou GI, Papachristou DJ, Avula H, et al. Obesity increases the severity of acute pancreatitis: performance of APACHE-O score and correlation with the inflammatory response. Pancreatology 2006; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/50\">",
"      Dom&iacute;nguez-Mu&ntilde;oz JE, Carballo F, Garc&iacute;a MJ, et al. Evaluation of the clinical usefulness of APACHE II and SAPS systems in the initial prognostic classification of acute pancreatitis: a multicenter study. Pancreas 1993; 8:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/51\">",
"      Williams M, Simms HH. Prognostic usefulness of scoring systems in critically ill patients with severe acute pancreatitis. Crit Care Med 1999; 27:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/52\">",
"      Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/53\">",
"      Mofidi R, Duff MD, Wigmore SJ, et al. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg 2006; 93:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/54\">",
"      Singh VK, Wu BU, Bollen TL, et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol 2009; 7:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/55\">",
"      Wu BU, Johannes RS, Sun X, et al. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut 2008; 57:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/56\">",
"      Papachristou GI, Muddana V, Yadav D, et al. Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. Am J Gastroenterol 2010; 105:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/57\">",
"      Windsor JA. A better way to predict the outcome in acute pancreatitis? Am J Gastroenterol 2010; 105:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/58\">",
"      Lankisch PG, Weber-Dany B, Hebel K, et al. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. Clin Gastroenterol Hepatol 2009; 7:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/59\">",
"      Bollen TL, van Santvoort HC, Besselink MG, et al. The Atlanta Classification of acute pancreatitis revisited. Br J Surg 2008; 95:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/60\">",
"      Vege SS, Chari ST. Organ failure as an indicator of severity of acute pancreatitis: time to revisit the Atlanta classification. Gastroenterology 2005; 128:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/61\">",
"      Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbr&egrave;re JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985; 120:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/62\">",
"      Bernard GR, Doig G, Hudson L, et al. Quantification of organ failure for clinical trials and clinical practice. Am J Respir Crit Care Med 1995; 151:A323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/63\">",
"      Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/64\">",
"      Le Gall JR, Klar J, Lemeshow S, et al. The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA 1996; 276:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/65\">",
"      Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990; 174:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/66\">",
"      Tenner S, Sica G, Hughes M, et al. Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology 1997; 113:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44504/abstract/67\">",
"      Simchuk EJ, Traverso LW, Nukui Y, Kozarek RA. Computed tomography severity index is a predictor of outcomes for severe pancreatitis. Am J Surg 2000; 179:352.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5639 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-125.69.132.100-EF8B9C69FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44504=[""].join("\n");
var outline_f43_29_44504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13832850\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF ACUTE PANCREATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical judgment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Older age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alcoholic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Short time interval to symptom onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Organ failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LABORATORY AND RADIOLOGIC PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hemoconcentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13833085\">",
"      Blood urea nitrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13833093\">",
"      Serum creatinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other serum markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4314399\">",
"      Chest radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3192492\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3192392\">",
"      MRI and MRCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SCORING SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ranson's criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      The APACHE II score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Systemic inflammatory response syndrome score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      BISAP score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13833427\">",
"      Harmless acute pancreatitis score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Organ failure-based scores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CT severity index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      AGA GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5639\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5639|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/5/37979\" title=\"table 1\">",
"      Ranson criteria pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/25/3483\" title=\"table 2\">",
"      Features SIRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/41/12956\" title=\"table 3\">",
"      CT grading acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?3/8/3205?source=related_link\" title=\"calculator 1\">",
"      Calculator: APACHE II scoring system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?7/16/7425?source=related_link\" title=\"calculator 2\">",
"      Calculator: Ranson criteria for pancreatitis prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?36/25/37264?source=related_link\" title=\"calculator 3\">",
"      Calculator: Bedside Index of Severity in Acute Pancreatitis (BISAP) score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/36/41537?source=related_link\">",
"      Patient information: Acute pancreatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_29_44505="Etiology and management of hoarseness in children";
var content_f43_29_44505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and management of hoarseness in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44505/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44505/contributors\">",
"     Craig H Zalvan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44505/contributors\">",
"     Jacqueline Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44505/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/29/44505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/29/44505/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/29/44505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Hoarseness\" or \"dysphonia\" is the term used to describe a change in the quality of the voice. The voice quality can be breathy, strained, fatigued, rough, tremulous, or weak; it may have a change in pitch or abnormal resonance. The prevalence of hoarseness in children ranges from 4 to 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Hoarseness can be caused by any process that affects the structure or function of the larynx. Etiologic categories include infection, inflammation, trauma, obstruction or infiltration, and congenital anomalies (",
"    <a class=\"graphic graphic_table graphicRef73274 \" href=\"mobipreview.htm?0/42/686\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, most hoarseness has a benign or self-limited cause (eg, vocal abuse or misuse) and can be managed with education, watchful waiting, and voice therapy. In addition, the growth of the vocal folds and laryngeal apparatus, change in habits, and change in the hormonal milieu that occur during puberty often contribute to improved voice quality. Surgery is reserved for persistent lesions with noted anatomic alterations.",
"   </p>",
"   <p>",
"    The etiology and management of hoarseness in children will be reviewed here. The evaluation of the child with hoarseness is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4102?source=see_link\">",
"     \"Evaluation of the child with hoarseness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MUCOSAL LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hoarseness in children is most often because of benign lesions of the vocal folds (eg, nodules, polyps, hemorrhage, hematoma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocal fold nodules are the most common cause of chronic hoarseness in school-aged children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority of these lesions occur in boys, particularly at the age of nine years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/6\">",
"     6",
"    </a>",
"    ]. Vocal fold nodules usually are located on the anterior free edge of the vocal fold at the point of greatest amplitude of vibration (the junction of the anterior one-third and the posterior two-thirds of the vocal fold). They develop from repeated trauma and abuse to the vocal folds (eg, screaming or shouting) that cause an inflammatory reaction with fibrotic healing. Vocal fold nodules are usually bilateral and can range in size from slightly raised hyperkeratotic lesions to larger broad-based lesions that prevent closure of the vocal folds.",
"   </p>",
"   <p>",
"    The symptoms of vocal nodules vary depending upon the size: small lesions may cause mild raspiness and roughness of the voice, whereas large lesions may cause breathiness because of incomplete closure of the vocal folds.",
"   </p>",
"   <p>",
"    Speech therapy is the most widely accepted treatment for vocal fold nodules; resolution or significant improvement typically is seen within three to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Microlaryngeal surgery may be indicated for persistent and highly dysfunctional nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Children who require surgery also should receive voice therapy to address the underlying vocal abuse or misuse, as vocal fold nodules can recur in as little as three days if vocal habits are not changed.",
"   </p>",
"   <p>",
"    Vocal fold nodules can be accompanied by other lesions of the vocal folds including hemorrhage, vascular varices, and hematoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/10\">",
"     10",
"    </a>",
"    ]. The pathogenesis of these lesions is similar to that of vocal fold nodules: vocal abuse leading to inflammatory reaction with fibrotic healing. The treatment of these processes mirrors that of vocal fold nodules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocal fold polyps are most common in adult males and occur rarely in children. Vocal fold polyps are fluid- and fibrin-filled lesions that occur at the free edge of the vocal fold in the superficial layer of the lamina propria. These lesions tend to appear unilaterally and usually are located at the junction of the anterior one-third and posterior two-thirds of the vocal folds. Trauma, chronic irritation, reflux, smoking, and muscle tension dysphonia may contribute to their formation. The symptoms of vocal fold polyps include hoarseness, diplophonia (having two different voice tones at the same time), raspiness, and breathiness. Surgical treatment is often necessary, although voice therapy is usually attempted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Muscle tension dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have a strained, easily tired voice may have some degree of muscle tension dysphonia. Muscle tension dysphonia occurs when the muscles of the larynx attempt to compensate for mucosal abnormality by contracting abnormally. This can lead to a vicious cycle of microtrauma to the vocal cords and resultant dysphonia, which in turn leads to the recruitment of additional counterproductive vocal mechanisms characterized by strain, excess muscle tension, and glottic compression. The end result is a narrowing of the arytenoids, false vocal folds, true vocal folds, or the entire larynx. Muscle tension dysphonia is treated with speech therapy and a change in the vocal habits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VOCAL FOLD GRANULOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocal fold granulomas are highly vascular lesions of nonspecific granulation tissue that usually appear in the posterior glottis associated with one, and occasionally both, arytenoids. Vocal fold granulomas occur most often secondary to intubation-associated trauma and prolonged intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/11\">",
"     11",
"    </a>",
"    ], but also occur in association with gastroesophageal reflux disease (GERD), laryngeal trauma, habitual throat clearing, and vocal misuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Gastroesophageal reflux is thought to be an important factor in the development and prolongation of vocal fold granuloma.",
"   </p>",
"   <p>",
"    Children with vocal fold granulomas usually present with hoarseness, diplophonia, breathiness, dysphagia, vocal fatigue, cough, or the feeling of a lump in the throat (globus sensation).",
"   </p>",
"   <p>",
"    The treatment of vocal fold granulomas depends upon the cause. Voice therapy can help to reverse or prevent poor vocal behaviors. Microlaryngeal surgery is reserved for lesions that obstruct the airway and persist despite optimal medical intervention. Management of gastroesophageal reflux is essential for those patients in whom GERD is a contributing factor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VOCAL FOLD PARALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocal fold paralysis is one of the most common laryngeal abnormalities of childhood. Bilateral vocal fold paralysis occurs with approximately the same frequency as unilateral vocal fold paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/14\">",
"     14",
"    </a>",
"    ]. Children with congenital vocal fold paralysis have a high rate of spontaneous return of function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of vocal fold paralysis in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iatrogenic, most commonly associated with cardiothoracic surgery, thyroidectomy, and tracheoesophageal fistula repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Idiopathic, probably the result of viral infection and autoimmune disease",
"     </li>",
"     <li>",
"      Neurologic, including Arnold-Chiari malformation, posterior fossa tumor, meningomyelocele, cerebral agenesis, and hydrocephalus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5994?source=see_link\">",
"       \"Hydrocephalus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Injury or compression of the recurrent laryngeal nerve, which may occur because of stretching of the neck during breech delivery or because of intrathoracic lesions (eg, aberrant great vessels, left heart failure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one retrospective review of 113 children with congenital vocal cord paralysis, 37 percent of the cases were idiopathic; 26 percent were associated with neurologic disorders; 13 percent were associated with difficult delivery; and 5 percent were associated with cardiac malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of vocal fold paralysis are related to the functions of the vocal folds: voice, airway protection, and cough. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4102?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of the child with hoarseness\", section on 'Physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newborn infants with unilateral vocal fold paralysis may have an absent or weak cry. Signs and symptoms of aspiration may be present (eg, coughing with swallowing and recurrent pneumonia). Children with unilateral vocal fold paralysis typically present with decreased volume and power of voice and hoarseness that has a breathy, raspy quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with bilateral vocal fold paralysis may be asymptomatic for the first six months of life. This is because the vocal folds tend to assume a midline position in bilateral paralysis (",
"    <a class=\"graphic graphic_picture graphicRef76725 \" href=\"mobipreview.htm?42/45/43743\">",
"     picture 1",
"    </a>",
"    ), which protects the airway and permits a normal cry. However, as the child's activity level (and oxygen requirement) increases, symptoms such as dyspnea and stridor become more apparent. Concomitant upper respiratory tract infection or edema of the vocal folds may cause abrupt airway compromise, resulting in respiratory distress and stridor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vocal fold paralysis can be confirmed by flexible nasolaryngoscopy in the awake child. Direct laryngoscopy in the operating room may be necessary if the child is difficult to examine, if the larynx is poorly visualized, or to rule out other abnormalities of the glottic and subglottic region. In patients with unilateral vocal fold paralysis, the ability of the contralateral vocal fold to compensate and the degree of posterior glottic opening (or chink) should be evaluated. In all patients, the presence of additional anatomic pathology should be noted.",
"   </p>",
"   <p>",
"    Children with vocal fold paralysis should undergo additional evaluation to determine the underlying etiology. A chest radiograph and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow should be performed to rule out abnormalities of the chest and esophagus. Magnetic resonance imaging (MRI) of the head and computed tomography (CT) of the chest may be necessary to rule out associated neurologic and thoracic abnormalities. Electromyography, although difficult to perform in children and not universally available, may provide additional diagnostic and prognostic information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Unilateral paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for intervention in children with unilateral vocal fold paralysis is based upon the degree of hoarseness and the risk of aspiration. Voice and speech therapy is directed to teaching children to compensate with the nonaffected vocal fold. The majority will improve with speech therapy; swallow therapy may help in cases of mild aspiration.",
"   </p>",
"   <p>",
"    Children who have gross aspiration and severe phonatory difficulty may require surgical intervention to medialize the paralyzed vocal fold. Medialization permits approximation of the vocal folds to protect the airway and improve voice quality. The medialization procedure varies depending upon the expected duration of paralysis as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If short-term paralysis is expected (eg, secondary to nerve trauma during surgery), the vocal fold can be injected with Gelfoam, fat, or collagen to provide temporary medialization.",
"     </li>",
"     <li>",
"      Medialization thyroplasty can be performed in children with long-term vocal fold paralysis. In this procedure a small window is created in the thyroid cartilage at the level of the vocal folds; silastic, Gortex, or hydroxyapatite material is then inserted into the window to help medialize the vocal fold.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bilateral paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of children with bilateral vocal fold paralysis, the vocal folds meet in the midline. Chronic respiratory insufficiency and stridor, rather than aspiration, are the major symptoms. Surgical procedures are necessary to lateralize, or open, the vocal folds. The goal of treatment is to provide an adequate airway while preventing aspiration. Tracheotomy is required in 50 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/15\">",
"     15",
"    </a>",
"    ]. Other surgical techniques that should only be considered in children with permanent vocal fold paralysis include laser arytenoidectomy, cordotomy, and vocal fold lateralization. These procedures are usually performed after tracheotomy in an attempt to achieve a functional voice and an adequate airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LARYNGITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute laryngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute laryngitis is defined as an inflammation of the mucosa of the larynx and can be caused by acute infection or vocal strain. The most common causes of laryngitis in children are related to viral respiratory tract infections, ranging from the common cold to mumps and measles. In addition to dysphonia, a child with a viral illness may have a low-grade fever, malaise, myalgias, rhinorrhea, cough, and mild dysphagia; mouth breathing secondary to nasal congestion also can cause drying of the vocal fold mucosa and resultant hoarseness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/5\">",
"     5",
"    </a>",
"    ]. Secondary bacterial infections should be considered in children who have fever, purulent exudate, or progressive pain, and fungal etiologies must be excluded in immunocompromised children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/20\">",
"     20",
"    </a>",
"    ]. Acute vocal strain (eg, because of screaming at a football game) can cause submucosal vocal cord hemorrhage and edema with resultant hoarseness.",
"   </p>",
"   <p>",
"    Acute laryngitis is usually a self-limited process and is treated conservatively with hydration, humidification, voice rest, salt-water gargles, and reassurance. Antipyretics and decongestants may be prescribed if warranted. Whispering can increase the trauma and must be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute laryngotracheitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because they have smaller airways, children are more susceptible to edema and inflammation of the subglottic airway than are adults. Children younger than five years of age may develop laryngotracheitis (croup). Parainfluenzae virus is the most common viral cause of laryngotracheitis; however, other viral infections can have similar clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=see_link&amp;anchor=H10#H10\">",
"     \"Parainfluenza viruses in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The child with laryngotracheitis typically has a hoarse voice and a characteristic \"barking\" cough. Laryngotracheitis usually begins as an upper respiratory tract infection; however, the infection fails to resolve, and the child develops progressively worsening cough, dyspnea, and chest wall retractions.",
"   </p>",
"   <p>",
"    The diagnosis is made from the clinical presentation. Radiographs of the neck may reveal the classic \"steeple sign\" formed by edema of the subglottic tissues (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52418 graphicRef64512 \" href=\"mobipreview.htm?38/42/39585\">",
"     image 1A-B",
"    </a>",
"    ). Radiographs are not necessary to make the diagnosis and usually are obtained to exclude epiglottitis or retropharyngeal abscess. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of croup is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link\">",
"     \"Approach to the management of croup\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chronic laryngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic laryngitis is defined by more than three months of hoarseness, dysphagia, dysphonia, and vocal fatigue. Children with chronic laryngitis may present with a chronic cough or chronic throat clearing. Characteristic findings in the larynx include thickened, tenacious mucus, edema of the mucosa of the false and true vocal folds, and thickening of the epithelial lining of the mucosa.",
"   </p>",
"   <p>",
"    In contrast to acute laryngitis, chronic laryngitis usually has a noninfectious etiology. Chronic laryngitis can be caused by the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure to environmental irritants (dry air, solvents, industrial pollution, and some household products)",
"     </li>",
"     <li>",
"      Environmental allergy (new products, dust, cockroach feces, and other allergens)",
"     </li>",
"     <li>",
"      Chronic sinusitis with post-nasal drip",
"     </li>",
"     <li>",
"      Medications (eg, inhaled steroids, anticholinergics, and antihistamines)",
"     </li>",
"     <li>",
"      Chronic dehydration",
"     </li>",
"     <li>",
"      Gastroesophageal reflux",
"     </li>",
"     <li>",
"      Chronic systemic disease (eg, untreated or undertreated hypothyroidism, sarcoidosis, amyloidosis, granulomatosis with polyangiitis [Wegener's])",
"     </li>",
"     <li>",
"      Malignancy (eg, lymphoma, sarcoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of chronic laryngitis depends upon the underlying etiology and may involve avoidance of environmental irritants and allergens, treatment of allergic rhinitis, treatment of sinusitis, humidification, increased hydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/21\">",
"     21",
"    </a>",
"    ], and correction of any underlying systemic or metabolic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     GASTROESOPHAGEAL REFLUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another major cause of hoarseness in children is gastroesophageal reflux disease (GERD) and associated laryngopharyngeal reflux (LPR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/22\">",
"     22",
"    </a>",
"    ]. Children may present with hoarseness, dysphagia, a chronic cough, recurrent vomiting, chronic throat clearing, the feeling of a lump in the throat (globus sensation), a bitter taste in the oral cavity, and an occasional feeling of respiratory obstruction secondary to laryngospasm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17561?source=see_link\">",
"     \"Approach to chronic cough in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laryngoscopic findings include vocal fold nodules, polyps, granuloma, or edema; laryngeal or tracheal stenosis; laryngospasm; subglottic edema; mucosal erythema, hyperemia, hypertrophy, or granuloma; laryngeal edema; and thick mucus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of GERD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CONGENITAL ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies of the larynx that cause hoarseness include webs, clefts, cysts (",
"    <a class=\"graphic graphic_picture graphicRef69715 \" href=\"mobipreview.htm?2/39/2672\">",
"     picture 2",
"    </a>",
"    ), and hemangiomas. Laryngeal clefts and cysts are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37543?source=see_link\">",
"     \"Congenital anomalies of the larynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laryngeal webs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal webs, a rare congenital anomaly, are caused by failure of resorption of the epithelial layer that obliterates the laryngeal opening in normal development. Failure of resorption results in incomplete separation of the vocal folds (",
"    <a class=\"graphic graphic_picture graphicRef57415 \" href=\"mobipreview.htm?37/51/38719\">",
"     picture 3",
"    </a>",
"    ). Webs can occur anywhere along the anterior or posterior larynx. A complete web, or atresia of the larynx, is incompatible with life and requires tracheotomy immediately after birth. Laryngeal webs also can result from trauma to the airway (eg, because of intubation, traumatic injury, or prior surgical manipulation). (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Trauma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Approximately 10 percent of patients with laryngeal webs have other associated anomalies, principally of the upper respiratory tract (eg, subglottic stenosis, submucous cleft palate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In addition, laryngeal webs are associated with cardiac defects (particularly ventricular septal defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/5,26\">",
"     5,26",
"    </a>",
"    ]) and may occur in conjunction with 22q11 deletion as part of the DiGeorge and velocardiofacial syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=see_link\">",
"     \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/250?source=see_link&amp;anchor=H15#H15\">",
"     \"Syndromes with craniofacial abnormalities\", section on 'Velocardiofacial (Shprintzen) syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with laryngeal webs usually present in infancy with respiratory distress and an unusual cry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]. Symptoms in those who present later in life include hoarse or weak voice, breathiness, and varying degrees of dyspnea and stridor depending upon the degree of airway compromise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of laryngeal webs depends upon the degree of airway obstruction. Simple anterior commissure webs are treated surgically, either by a simple lysis of the web with a CO2 laser or sharp dissection with a knife. Laryngeal reconstruction, laryngeal stent, and tracheotomy may be indicated in patients with webs that include larger portions of the anterior and posterior glottis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laryngeal clefts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngotracheoesophageal clefts result from an embryologic failure of fusion of the cricoid cartilage and tracheoesophageal septum. The smallest clefts involve only the interarytenoid region, whereas the largest clefts involve the full length of the posterior glottis, cricoid, subglottis, and trachea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37543?source=see_link&amp;anchor=H13#H13\">",
"     \"Congenital anomalies of the larynx\", section on 'Laryngeal clefts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with posterior laryngeal clefts may present with increased secretions, feeding difficulty, failure to thrive, wheezing, stridor, noisy breathing, aspiration, respiratory distress, recurrent pulmonary infections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hoarseness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is based upon a high index of suspicion and is supported by modified",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow that shows leakage of barium into the airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/28\">",
"     28",
"    </a>",
"    ]. Diagnosis is confirmed with laryngopharyngoscopy that should include direct palpation of the interarytenoid area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment for laryngotracheoesophageal clefts depends upon the type of cleft and severity of associated symptoms. Minor clefts sometimes can be managed without surgery if medical therapy can control gastroesophageal reflux and aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Operative repair typically requires involvement of the otolaryngologist and thoracic surgeon, depending on the length of the cleft. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal hemangiomas rarely cause hoarseness in newborns. Hemangiomas of the skin are present in approximately one-half of patients with subglottic hemangiomas. When cutaneous hemangiomas occur in a \"beard\" distribution, there is an increased risk of symptomatic airway hemangiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/30\">",
"     30",
"    </a>",
"    ]. Symptoms of respiratory obstruction worsen with crying or intercurrent upper respiratory tract infection. Intervention (eg, steroid therapy, laser therapy, or tracheostomy) is required for hemangiomas that compromise the airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/5,31-33\">",
"     5,31-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PSYCHOGENIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychogenic dysphonia refers to a variety of voice disorders resulting from trauma, anxiety, depression, personality disorders, and conversion reactions. These disorders can manifest with aphonia, whispering, high-pitched voicing with voice breaks, or a strained voice. Psychogenic dysphonia is usually a defense mechanism or an adaptive behavior to obtain primary and secondary gain. The disorder usually manifests after a traumatic event, a viral syndrome, or during the anniversary of a traumatic event (eg, the death of a parent or relative).",
"   </p>",
"   <p>",
"    Children who have psychogenic dysphonia typically have a normal cry, laugh, and cough. Psychogenic dysphonia is a diagnosis of exclusion; patients must have a normal physical examination, including laryngoscopy. The treatment of psychogenic dysphonia centers on the diagnosis and treatment of the underlying psychologic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Psychogenic stridor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychogenic stridor is a severe form of psychogenic dysphonia. It also is called paradoxical vocal cord dysfunction, Munchausen stridor, factitious asthma, pseudoasthma, and \"vocal cord dysfunction presenting as asthma\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with this disorder may have a history of prior psychiatric illness, including depression, personality disorder, or post traumatic stress disorder, or they may have a history of childhood sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In one study comparing adolescents with vocal cord dysfunction to those with asthma, patients with paradoxical vocal fold motion had higher levels of anxiety and more frequent diagnoses of generalized anxiety disorder and separation anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/40\">",
"     40",
"    </a>",
"    ]. Some patients have concomitant asthma or have been misdiagnosed with asthma; these patients may develop iatrogenic Cushing's syndrome after high dose glucocorticoid treatment for putative refractory asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20595323\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents who have psychogenic stridor have a normal laugh and cry and resolution of the stridor during sleep, or in some cases, when the patient is unaware of being observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/35,43\">",
"     35,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may present with significant respiratory distress and dramatic inspiratory stridor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/44\">",
"     44",
"    </a>",
"    ]. Adventitious sounds are loudest above the throat and are less audible through the chest wall, where the sound is attenuated by transmission through the airways and the pulmonary parenchyma. Acute respiratory distress may be of such severity that patients are treated with intubation or tracheotomy to restore airway patency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/42,45\">",
"     42,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because psychogenic stridor can coexist with true asthma, a thorough evaluation for asthma is essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Clinical features that support a diagnosis of psychogenic stridor include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/37,48,49\">",
"     37,48,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More subjective difficulty on inspiration than expiration",
"     </li>",
"     <li>",
"      Minimal response to aggressive asthma treatment",
"     </li>",
"     <li>",
"      A flattened inspiratory flow-volume loop (",
"      <a class=\"graphic graphic_figure graphicRef76811 \" href=\"mobipreview.htm?34/31/35325\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Normal pulse oximetry, pulmonary function tests, and arterial blood gas measurements",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of psychogenic stridor requires a high index of suspicion. Airway radiographs and fluoroscopy may demonstrate paradoxical vocal cord motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/42,50\">",
"     42,50",
"    </a>",
"    ]. Visualization of the cords using a flexible fiberoptic laryngoscope confirms the diagnosis by revealing normal laryngeal architecture and paradoxical motion of the vocal folds, ie, adduction during inspiration and abduction during phonation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of psychogenic stridor is directed at the underlying psychologic etiology and involves psychotherapy coupled with voice therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Puberphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Puberphonia, or mutational falsetto, is a disorder that occurs around puberty. It is defined by the failure of the voice to change from the higher-pitch of early childhood to the lower-pitch of adulthood and may be caused by a maladaptation to the psychological changes of puberty. Muscular incoordination, hyperfunction of the cricothyroid muscle, and psychological uncertainty are contributing factors. Children with puberphonia often have associated breathiness and decreased power of projection. Puberphonia is usually treated with voice therapy and problem-directed psychotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ENDOCRINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of hormonal conditions can cause voice changes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hypothyroidism may have a coarse, raspy, breathy, and low-pitched voice resulting from edema of the vocal folds that alters vocal fold vibration. Proper hormone replacement and voice therapy can lead to improvement.",
"     </li>",
"     <li>",
"      Oral contraceptive medications, hormonal therapy with androgens, and increased endogenous androgen activity occasionally can cause a coarse, low-pitched, raspy, or breathy voice. Alteration of therapy, treatment of the underlying abnormality, and voice therapy can lead to improvement.",
"     </li>",
"     <li>",
"      The increased water content of the soft tissues and laxity of ligamentous insertions during pregnancy can alter the physical properties of the vocal folds, resulting in breathiness, raspiness, and a lowered vocal pitch. In addition, high pressure in the glottis from pushing during childbirth can cause acute injury to the soft tissues of the vocal folds, resulting in vocal fold hemorrhage, tears, and inflammation. Pregnancy-related voice change is usually treated with humidification, hydration, and reassurance, after a thorough endoscopic evaluation. Voice therapy is reserved for the cases in which conservative measures fail.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is another important cause of acute and chronic hoarseness in children. The repetitive trauma of vocal abuse can result in vocal nodules, polyps, and scarring as discussed above. In addition, the mucosa of the respiratory tract, including the larynx, can be injured through exposure or ingestion, and the larynx can be injured by blunt or penetrating trauma. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mucosal lesions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Mucosal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure injury to the respiratory mucosa through caustic ingestion, inhalation injury, and exposure to noxious chemicals and fumes can cause acute hoarseness, loss of voice, pain, and, in severe cases, stridor and respiratory distress. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediate attention to the respiratory status in patients with respiratory exposure is of primary importance. Patients who have stridor, drooling, nasal flaring, retractions, or tachypnea, or are using accessory muscles to breathe, are at risk for life-threatening airway obstruction and must be managed accordingly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients without significant respiratory distress can undergo flexible fiberoptic laryngoscopy in a more controlled setting to evaluate the extent of mucosal injury, which can range from erythema or edema to ulceration, burns, and even perforation.",
"   </p>",
"   <p>",
"    The management of mucosal injury depends upon the severity and can range from humidification and voice rest to immediate intubation or tracheotomy. Caustic laryngeal injury can lead to scarring, web formation, and glottic and subglottic stenosis, all which can cause chronic dysphonia. Surgical repair is possible in some cases; however, results are poor secondary to decreased ability to heal and chronic scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Intubation injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;During intubation, a child's airway is particularly susceptible to injury from endotracheal manipulation. The relatively small diameter of the larynx and loose approximation of the mucosa to the underlying soft tissue permit early-onset edema and airway compromise. These changes can cause pain, breathiness, raspiness, and a change in pitch after extubation. The vocal folds also can be injured during nasogastric intubation.",
"   </p>",
"   <p>",
"    Vocal fold edema, ulceration, lacerations, and granuloma are common after long-term intubation. Because these lesions can be exacerbated by gastroesophageal reflux, measures to control reflux should be considered during the period of intubation. In addition, long-term intubation can lead to subglottic and glottic stenosis, which can cause respiratory distress, stridor, and hoarseness. No data exists regarding the amount of time a child can tolerate intubation without incurring significant risk of permanent airway injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Blunt neck trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt neck trauma in children is most often because of motor vehicle collisions, bicycle collisions, sports activity, falls, and fights. Blunt neck trauma can injure any of the anatomic structures of the larynx that are necessary for voice production. Children who have sustained blunt neck injury should also be evaluated for associated injuries to the head, cervical spine, and chest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4102?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of the child with hoarseness\", section on 'Anatomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who have sustained blunt neck trauma may present with voice change (breathy, raspy), hemoptysis, or frank respiratory distress. Immediate evaluation of the cervical airway is of utmost importance. Children with respiratory distress, crepitus, subcutaneous emphysema, stridor, tracheal deviation, cervical spine tenderness, or asymmetric carotid pulses require immediate establishment of a patent airway, stabilization of the cervical spine, intravenous access and surgical consultation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients without indications of potential life-threatening injury can undergo flexible fiberoptic laryngoscopy in a more controlled setting to evaluate the airway for edema, hematoma, laceration, and the vocal folds for mobility.",
"   </p>",
"   <p>",
"    The management of children with blunt neck trauma depends upon the severity of injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with any of the laryngoscopic findings described above should be further evaluated with computed tomography (CT) of the neck with fine cuts through the larynx, which will determine the need for further intervention and possible surgical repair.",
"     </li>",
"     <li>",
"      Children with normal vocal fold movement and no evidence of mucosal injury should be monitored closely for the development of respiratory symptoms. Humidification, oxygen saturation monitoring, and serial examination with flexible fiberoptic laryngoscopy will determine the need for further intervention during a period of observation. Injuries to the airway may not be appreciated upon initial physical examination and may progress to cause airway obstruction as late as 48 hours after the injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Penetrating trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating trauma to the neck requires immediate evaluation, control of the airway, and urgent evaluation by an otolaryngologist. Respiratory distress, vascular compromise, and esophageal injury are potential sequelae of penetrating neck trauma. Complete evaluation may include flexible fiberoptic laryngoscopy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    esophagram, angiography, and operative endoscopy and exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Benign tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign tumors of the larynx are a rare cause of hoarseness in children. These tumors include papillomas, hemangiomas, cystic hygromas, and neurofibromas. Benign laryngeal tumors are usually slow-growing and cause symptoms through interference with vocal fold mobility, compression of surrounding structures, and occlusion of the airway. Symptoms include breathiness, raspiness, voice breaks, altered pitch, and respiratory compromise. The diagnosis of benign tumors relies upon flexible fiberoptic laryngoscopy, stroboscopy, and possible operative laryngoscopy. CT scan of the neck with fine cuts through the larynx can help to delineate the extent of the tumor and the possible etiology. Management of benign tumors typically involves surgical excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Papillomatosis (HPV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent respiratory papillomatosis (RRP) is the most common benign laryngeal tumor in children. RRP is typically diagnosed between the ages of two and three years, and most children are diagnosed before five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. RRP is thought to be caused by acquisition of HPV during passage through the birth canal of an infected mother [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/54\">",
"     54",
"    </a>",
"    ]. HPV6 and HPV11 are most commonly involved, although HPV16 has been rarely observed and may be associated with an increased risk of malignant degeneration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for head and neck cancer\", section on 'Human papillomavirus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for RRP include being the firstborn child, vaginal delivery, and having a teenage mother who has genital condylomata [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. In one large retrospective cohort study, infants born to mothers with a history of genital warts were 231 times more likely (95% CI 135-396) to develop respiratory papillomatosis than those born to mothers without such a history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/57\">",
"     57",
"    </a>",
"    ]. However, among infants born to women with such a history, the risk of RRP was less than 1 percent.",
"   </p>",
"   <p>",
"    HPV infects squamous mucosa, both naturally occurring and because of metaplasia of respiratory epithelium. Metaplasia of the respiratory epithelium can occur as a result of chronic environmental exposure or repeated trauma. Symptoms of RRP include hoarseness, breathiness, occasional respiratory distress, intermittent respiratory obstruction, and aphonia. Physical examination typically reveals multiple verrucous, polypoid growths overlying the true vocal folds, false vocal folds, subglottic region, and trachea.",
"   </p>",
"   <p>",
"    In a small number of young children who have aggressive lesions, tracheotomy may be required for airway control. However, tracheotomy may be associated with an increased risk of recurrence and development of lower airway papillomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/52\">",
"     52",
"    </a>",
"    ]. In children who have a less aggressive course, the treatment of RRP usually involves microlaryngeal surgery to debulk the lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Most children with RRP require multiple surgical treatments before puberty (when RRP typically regresses), particularly if they were diagnosed before the age of three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one review of 399 children with juvenile-onset RRP, the mean number of surgical procedures per child was 4.4 per year (range less than one to 19) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/53\">",
"     53",
"    </a>",
"    ]. The time interval between surgical procedures depends upon the individual patient's severity.",
"   </p>",
"   <p>",
"    Investigational approaches to RRP include interferon, photodynamic therapy, carbinol,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    , vitamin A, pulsed-dye laser therapy, and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/52,60,61\">",
"     52,60,61",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/34/14886?source=see_link\">",
"     Cidofovir",
"    </a>",
"    , an antiviral agent, has been used to treat RRP by injecting the base of the papillomas after they are resected. Anecdotal evidence supports some benefit, with a decrease in both the frequency and severity of recurrence, although one small randomized trial showed no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/62-65\">",
"     62-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of RRP should include comprehensive education regarding the condition and information regarding support groups (eg, the RRP Foundation,",
"    <a class=\"external\" href=\"file://www.rrpf.org/\">",
"     www.rrpf.org",
"    </a>",
"    , or the international RRP ISA center,",
"    <a class=\"external\" href=\"file://www.rrpwebsite.org/\">",
"     www.rrpwebsite.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/29/44505/abstract/61,66\">",
"     61,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Malignant tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant tumors of the pediatric larynx are even rarer than benign tumors. Malignant tumors can be associated with rapid progression of stridor and airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rhabdomyosarcoma is the most common childhood tumor to affect the larynx, followed by other members of the sarcoma group. Other tumors that occur in the pediatric larynx include squamous cell carcinoma, chondrosarcoma, lymphoma, plasmacytoma, mucoepidermoid carcinoma, metastatic carcinoma, and neuroectodermal tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is based upon laryngoscopic examination and biopsy. Radiographic evaluation including CT, MRI, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow are commonly required. The treatment is based upon tumor histology. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/29/26066?source=see_link\">",
"       \"Patient information: Laryngitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hoarseness can be caused by any process that affects the structure or function of the larynx (",
"      <a class=\"graphic graphic_table graphicRef73274 \" href=\"mobipreview.htm?0/42/686\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hoarseness in children is most often caused by benign lesions of the vocal folds (eg, nodules, polyps, hemorrhage, hematoma). Vocal fold granulomas (predisposing factors include history of endotracheal intubation, gastroesophageal reflux disease, laryngeal trauma, habitual throat clearing, and vocal misuse) and vocal fold paralysis also may cause hoarseness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mucosal lesions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Vocal fold granuloma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Vocal fold paralysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hoarseness also may be caused by inflammation of the larynx",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subglottic airway. Causes of acute or chronic inflammation include infection (eg, parainfluenza virus), vocal strain, chronic cough or throat clearing, environmental irritants, and systemic disease (eg, hypothyroidism, sarcoidosis, malignancy). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laryngitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital anomalies of the larynx that cause hoarseness include webs, clefts, cysts, and hemangiomas. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Congenital anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychogenic dysphonia refers to a variety of voice disorders resulting from trauma, anxiety, depression, personality disorders, and conversion reactions. It is a diagnosis of exclusion. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Psychogenic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hormonal causes of hoarseness include hypothyroidism, hormonal medications (eg, oral contraceptives, androgen therapy, androgen excess, pregnancy). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Endocrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mucosal injury (eg, caustic ingestion, inhalation injury), intubation injury, and blunt or penetrating neck trauma may result in acute or chronic hoarseness in children. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign tumors of the larynx that may cause hoarseness include papillomas, hemangiomas, cystic hygromas, and neurofibromas. Rhabdomyosarcoma is the most common malignant tumor to affect the larynx. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/1\">",
"      Silverman EM. Incidence of chronic hoarseness among school-age children. J Speech Hear Disord 1975; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/2\">",
"      Duff MC, Proctor A, Yairi E. Prevalence of voice disorders in African American and European American preschoolers. J Voice 2004; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/3\">",
"      Carding PN, Roulstone S, Northstone K, ALSPAC Study Team. The prevalence of childhood dysphonia: a cross-sectional study. J Voice 2006; 20:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/4\">",
"      Cohen SR, Thompson JW, Geller KA, Birns JW. Voice change in the pediatric patient. A differential diagnosis. Ann Otol Rhinol Laryngol 1983; 92:437.",
"     </a>",
"    </li>",
"    <li>",
"     Levitsky SE. Hoarseness. In: Primary pediatric care, 4th ed, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.1156.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/6\">",
"      Cornut G, Troillet-Cornut A. Childhood dysphonia: clinical and therapeutic considerations. Voice 1995; 4:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/7\">",
"      von Leden H. Vocal nodules in children. Ear Nose Throat J 1985; 64:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/8\">",
"      Wohl DL. Nonsurgical management of pediatric vocal fold nodules. Arch Otolaryngol Head Neck Surg 2005; 131:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/9\">",
"      Reilly JS. The \"singing-acting\" child: the laryngologist's perspective--1995. J Voice 1997; 11:126.",
"     </a>",
"    </li>",
"    <li>",
"     Bastian RW. Benign mucosal disorders. In: Otolaryngology head and neck surgery, Cummings CW, Frederickson JM, Harker LA, et al (Eds), Mosby, St. Louis 1986. p.1965.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/11\">",
"      Benjamin B, Croxson G. Vocal cord granulomas. Ann Otol Rhinol Laryngol 1985; 94:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/12\">",
"      Ward PH, Zwitman D, Hanson D, Berci G. Contact ulcers and granulomas of the larynx: new insights into their etiology as a basis for more rational treatment. Otolaryngol Head Neck Surg (1979) 1980; 88:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/13\">",
"      Kalach N, Gumpert L, Contencin P, Dupont C. Dual-probe pH monitoring for the assessment of gastroesophageal reflux in the course of chronic hoarseness in children. Turk J Pediatr 2000; 42:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/14\">",
"      de Gaudemar I, Roudaire M, Fran&ccedil;ois M, Narcy P. Outcome of laryngeal paralysis in neonates: a long term retrospective study of 113 cases. Int J Pediatr Otorhinolaryngol 1996; 34:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/15\">",
"      Daya H, Hosni A, Bejar-Solar I, et al. Pediatric vocal fold paralysis: a long-term retrospective study. Arch Otolaryngol Head Neck Surg 2000; 126:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/16\">",
"      Kenna MA. Consultation with the specialist. Hoarseness. Pediatr Rev 1995; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/17\">",
"      Shah RK, Harvey-Woodnorth G, Glynn A, Nuss RC. Perceptual voice characteristics in pediatric unilateral vocal fold paralysis. Otolaryngol Head Neck Surg 2006; 134:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/18\">",
"      Jacobs IN, Finkel RS. Laryngeal electromyography in the management of vocal cord mobility problems in children. Laryngoscope 2002; 112:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/19\">",
"      Wang CC, Chang MH, Wang CP, Liu SA. Prognostic indicators of unilateral vocal fold paralysis. Arch Otolaryngol Head Neck Surg 2008; 134:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/20\">",
"      Forrest LA, Weed H. Candida laryngitis appearing as leukoplakia and GERD. J Voice 1998; 12:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/21\">",
"      Chan RW, Tayama N. Biomechanical effects of hydration in vocal fold tissues. Otolaryngol Head Neck Surg 2002; 126:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/22\">",
"      Block BB, Brodsky L. Hoarseness in children: the role of laryngopharyngeal reflux. Int J Pediatr Otorhinolaryngol 2007; 71:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/23\">",
"      Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope 2001; 111:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/24\">",
"      Benjamin B. Chevalier Jackson Lecture. Congenital laryngeal webs. Ann Otol Rhinol Laryngol 1983; 92:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/25\">",
"      McHugh HE, Loch WE. Congenital webs of the larynx. Laryngoscope 1942; 52:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/26\">",
"      Shearer WT, Biller HF, Ogura JH, Goldring D. Congenital laryngeal web and interventricular septal defect. First reported cases. Am J Dis Child 1972; 123:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/27\">",
"      Strakowski SM, Butler MG, Cheek JW, et al. Familial laryngeal web in three generations with probable autosomal dominant transmission. Dysmorph Clin Genet 1988; 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/28\">",
"      Hartnick CJ, Cotton RT. Congenital laryngeal anomalies. Laryngeal atresia, stenosis, webs, and clefts. Otolaryngol Clin North Am 2000; 33:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/29\">",
"      Parsons DS, Stivers FE, Giovanetto DR, Phillips SE. Type I posterior laryngeal clefts. Laryngoscope 1998; 108:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/30\">",
"      Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a \"beard\" distribution. J Pediatr 1997; 131:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/31\">",
"      Al-Sebeih K, Manoukian J. Systemic steroids for the management of obstructive subglottic hemangioma. J Otolaryngol 2000; 29:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/32\">",
"      Madgy D, Ahsan SF, Kest D, Stein I. The application of the potassium-titanyl-phosphate (KTP) laser in the management of subglottic hemangioma. Arch Otolaryngol Head Neck Surg 2001; 127:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/33\">",
"      Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 1990; 85:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/34\">",
"      Baker J. Psychogenic dysphonia: peeling back the layers. J Voice 1998; 12:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/35\">",
"      Patterson R, Schatz M, Horton M. Munchausen's stridor: non-organic laryngeal obstruction. Clin Allergy 1974; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/36\">",
"      Skinner DW, Bradley PJ. Psychogenic stridor. J Laryngol Otol 1989; 103:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/37\">",
"      Christopher KL, Wood RP 2nd, Eckert RC, et al. Vocal-cord dysfunction presenting as asthma. N Engl J Med 1983; 308:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/38\">",
"      Martin RJ, Blager FB, Gay ML, et al. Paradoxical vocal cord motion in presumed asthmatics. Semin Respir Med 1987; 8:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/39\">",
"      Freedman MR, Rosenberg SJ, Schmaling KB. Childhood sexual abuse in patients with paradoxical vocal cord dysfunction. J Nerv Ment Dis 1991; 179:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/40\">",
"      Gavin LA, Wamboldt M, Brugman S, et al. Psychological and family characteristics of adolescents with vocal cord dysfunction. J Asthma 1998; 35:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/41\">",
"      Goldman J, Muers M. Vocal cord dysfunction and wheezing. Thorax 1991; 46:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/42\">",
"      Nastasi KJ, Howard DA, Raby RB, et al. Airway fluoroscopic diagnosis of vocal cord dysfunction syndrome. Ann Allergy Asthma Immunol 1997; 78:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/43\">",
"      Downing ET, Braman SS, Fox MJ, Corrao WM. Factitious asthma. Physiological approach to diagnosis. JAMA 1982; 248:2878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/44\">",
"      Morris MJ, Deal LE, Bean DR, et al. Vocal cord dysfunction in patients with exertional dyspnea. Chest 1999; 116:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/45\">",
"      Altman KW, Mirza N, Ruiz C, Sataloff RT. Paradoxical vocal fold motion: presentation and treatment options. J Voice 2000; 14:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/46\">",
"      Newman KB, Mason UG 3rd, Schmaling KB. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med 1995; 152:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/47\">",
"      O'Connell MA, Sklarew PR, Goodman DL. Spectrum of presentation of paradoxical vocal cord motion in ambulatory patients. Ann Allergy Asthma Immunol 1995; 74:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/48\">",
"      Corren J, Newman KB. Vocal cord dysfunction mimicking bronchial asthma. Postgrad Med 1992; 92:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/49\">",
"      Mobeireek A, Alhamad A, Al-Subaei A, Alzeer A. Psychogenic vocal cord dysfunction simulating bronchial asthma. Eur Respir J 1995; 8:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/50\">",
"      Shao W, Chung T, Berdon WE, et al. Fluoroscopic diagnosis of laryngeal asthma (paradoxical vocal cord motion). AJR Am J Roentgenol 1995; 165:1229.",
"     </a>",
"    </li>",
"    <li>",
"     Woodward GA. Neck trauma. In: Textbook of pediatric emergency medicine, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.1389.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/52\">",
"      Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child 2006; 91:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/53\">",
"      Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/54\">",
"      Shah KV, Stern WF, Shah FK, et al. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J 1998; 17:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/55\">",
"      Kashima HK, Shah F, Lyles A, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 1992; 102:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/56\">",
"      Quick CA, Watts SL, Krzyzek RA, Faras AJ. Relationship between condylomata and laryngeal papillomata. Clinical and molecular virological evidence. Ann Otol Rhinol Laryngol 1980; 89:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/57\">",
"      Silverberg MJ, Thorsen P, Lindeberg H, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/58\">",
"      Dedo HH, Yu KC. CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope 2001; 111:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/59\">",
"      Parsons DS, Bothwell MR. Powered instrument papilloma excision: an alternative to laser therapy for recurrent respiratory papilloma. Laryngoscope 2001; 111:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/60\">",
"      Hartnick CJ, Boseley ME, Franco RA Jr, et al. Efficacy of treating children with anterior commissure and true vocal fold respiratory papilloma with the 585-nm pulsed-dye laser. Arch Otolaryngol Head Neck Surg 2007; 133:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/61\">",
"      Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008; 118:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/62\">",
"      Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 2003; 113:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/63\">",
"      Mandell DL, Arjmand EM, Kay DJ, et al. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2004; 130:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/64\">",
"      McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol 2008; 117:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/65\">",
"      Chadha NK, James A. Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev 2012; 12:CD005053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/29/44505/abstract/66\">",
"      Zeitels SM, Casiano RR, Gardner GM, et al. Management of common voice problems: Committee report. Otolaryngol Head Neck Surg 2002; 126:333.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6303 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-1401E7A8BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44505=[""].join("\n");
var outline_f43_29_44505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MUCOSAL LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Muscle tension dysphonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VOCAL FOLD GRANULOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VOCAL FOLD PARALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Unilateral paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bilateral paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LARYNGITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute laryngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute laryngotracheitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chronic laryngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      GASTROESOPHAGEAL REFLUX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CONGENITAL ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laryngeal webs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laryngeal clefts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PSYCHOGENIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Psychogenic stridor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20595323\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Puberphonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ENDOCRINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Mucosal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Intubation injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Blunt neck trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Penetrating trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Benign tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Papillomatosis (HPV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Malignant tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6303\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6303|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/56/2959\" title=\"diagnostic image 1A\">",
"      Steeple sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/43/2751\" title=\"diagnostic image 1B\">",
"      Subglottic edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6303|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/31/35325\" title=\"figure 1\">",
"      Flow volume loops in airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6303|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/45/43743\" title=\"picture 1\">",
"      Bilateral vocal fold paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/39/2672\" title=\"picture 2\">",
"      Aryepiglottic fold cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/51/38719\" title=\"picture 3\">",
"      Anterior laryngeal web",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6303|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/42/686\" title=\"table 1\">",
"      DDx hoarseness child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17561?source=related_link\">",
"      Approach to chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=related_link\">",
"      Approach to the management of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37543?source=related_link\">",
"      Congenital anomalies of the larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4102?source=related_link\">",
"      Evaluation of the child with hoarseness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/29/26066?source=related_link\">",
"      Patient information: Laryngitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_29_44506="Cutaneous changes of Stevens Johnson Syndrome";
var content_f43_29_44506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67632%7EDERM%2F68458%7EDERM%2F82150%7EDERM%2F59418%7EALLRG%2F66134%7EEM%2F76141%7EEM%2F73805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67632%7EDERM%2F68458%7EDERM%2F82150%7EDERM%2F59418%7EALLRG%2F66134%7EEM%2F76141%7EEM%2F73805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous changes of Stevens-Johnson Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized eruption of lesions that initially had a target-like appearance but then became confluent, brightly erythematous, and bullous. The patient had extensive mucous membrane involvement and tracheobronchitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 3rd edition, Fitzpatrick TB, Johnson RA, Wolff K, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse erythema and large areas of desquamation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple bullae overlying diffuse erythema are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple bullae and large areas of desquamation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Usually caused by drugs, toxic epidermal necrolysis demonstrates widespread erythema and confluent vesiculation, leading to sloughing of the skin. Affected patients are at risk for hypernatremic dehydration and sepsis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous findings of Stevens Johnson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the vesicles and bulla that are characteristic of the cutaneous findings in Stevens Johnson syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucosal changes in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes similar to those observed in SJS/TEN can be observed also in erythema multiforme majus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44506=[""].join("\n");
var outline_f43_29_44506=null;
var title_f43_29_44507="Assessment macrosomia refs";
var content_f43_29_44507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    References",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. ACOG Practice Bulletin No.22: Fetal Macrosomia.  2000",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2.  Chauhan, SP, Sullivan, CA, Lutton, TC, et al.  J Perinatol 1995; 15:192.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3.  Chauhan, SP, Hendrix, NW, Magann, EF, et al. Obstet Gynecol 1998; 91:72.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4.  Combs, CA, Rosenn, B, Miodovnik, M, Siddiqi, TA. J Matern Fetal Med 2000; 9:55.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5.  Gilby, JR, Williams, MC, Spellacy, WN. J Reprod Med 2000; 45:936.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6.  Al-Inany, H, Alaa, N, Momtaz, M, Abdel Badii, M. Gynecol Obstet Invest 2001; 51:116.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7.  Pinette, MG, Pan, Y, Pinette, SG, et al.  J Ultrasound Med 1999; 18:813.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8.  Benacerraf, BE, Gelman, R, Frigoletto, FD.  Am J Obstet Gynecol 1988; 159:1118.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9.  Sokol, RJ, Chik, L, Dombrowski, MP, Zador, IE.  Am J Obstet Gynecol 2000; 182:1489.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10. Hirata, GI, Medearis, AL, Horenstein, J, et al.  Am J Obstet Gynecol 1990; 162:238.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11. Owen, P, Ogston, S.  Ultrasound Obstet Gynecol 1998; 11:110.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12. Shields, LE, Huff, RW, Jackson, GM, et al.  J Ultrasound Med 1993; 12:271.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13. Crane, JP, Kopta, MM, Welt, SI, Sauvage, JP.  Obstet Gynecol 1977; 50:205.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       14. Hedriana, HL, Moore, TR.  Am J Obstet Gynecol 1994; 170:1600.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15. Petrikovsky, BM, Oleschuk, C, Lesser, M, et al. J Clin Ultrasound 1997; 25:378.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       16. Gonen, R, Spiegel, D, Abend, M.  Obstet Gynecol 1996; 88:526.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       17. Henrichs, C, Magann, EF, Brantley, KL, et al.  J Reprod Med 2003; 48:339.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44507=[""].join("\n");
var outline_f43_29_44507=null;
var title_f43_29_44508="Amer Disabilities Act PI";
var content_f43_29_44508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Americans with Disabilities Act",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Title I of the",
"        <strong>",
"         Americans with Disabilities Act of 1990",
"        </strong>",
"        , which took effect July 26, 1992, prohibits private employers, state and local governments, employment agencies, and labor unions from discriminating against qualified individuals with disabilities in job application procedures; hiring; firing; advancement; compensation; job training; and other terms, conditions and privileges of employment. An individual with a disability is a person who:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\">",
"        Has a physical or mental impairment that substantially limits one or more major life activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Has a record of such an impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Is regarded as having such an impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A qualified employee or applicant with a disability is an individual who, with or without reasonable accommodation, can perform the essential functions of the job in question. Reasonable accommodation may include, but is not limited to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\">",
"        Making existing facilities used by employees readily accessible to and usable by persons with disabilities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Job restructuring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Modifying work schedules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reassignment to a vacant position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acquiring or modifying equipment or devices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adjusting modifying examinations, training materials, or policies, and providing qualified readers or interpreters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        An employer is required to make an accommodation to the known disability of a qualified applicant or employee if it would not impose an \"undue hardship\" on the operation of the employer's business. Undue hardship is defined as an action requiring significant difficulty or expense when considered in light of factors such as an employer's size, financial resources, and the nature and structure of its operation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        An employer is not required to lower quality or production standards to make an accommodation, nor is an employer obligated to provide personal use items such as glasses or hearing aids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medical examinations and inquiries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Employers may not ask job applicants about the existence, nature, or severity of a disability. Applicants may be asked about their ability to perform specific job functions. A job offer may be conditioned on the results of a medical examination, but only if the examination is required for all entering employees in similar jobs. Medical examinations of employees must be job related and consistent with the employer's business needs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug and alcohol abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Employees and applicants currently engaging in the illegal use of drugs are not covered by the ADA when an employer acts on the basis of such use. Tests for illegal drugs are not subject to the ADA's restrictions on medical examinations. Employers may hold illegal drug users and alcoholics to the same performance standards as other employees.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        EEOC enforcement of the ADA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The U.S. Equal Employment Opportunity Commission issued regulations to enforce the provisions of Title I of the ADA on July 26, 1991. The provisions originally took effect on July 26, 1992, and covered employers with 25 or more employees. On July 26, 1994, the threshold dropped to include employers with 15 or more employees.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44508=[""].join("\n");
var outline_f43_29_44508=null;
var title_f43_29_44509="Benefit of Rx of mild HTN";
var content_f43_29_44509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Cardiovascular benefit of treating mild hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 230px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reduced incidence of fatal and total coronary heart disease (CHD) events and strokes following antihypertensive therapy in 17 controlled studies involving almost 48,000 patients with mild to moderate hypertension. The number of patients having each of these events is depicted, with active treatment lowering the incidence of coronary events by 16 percent and stroke by 40 percent. However, the absolute benefit - as shown, in percent, by the numbers at the top of the graph - was much less. Treatment for approximately 4 to 5 years prevented a coronary event or a stroke in two percent of patients (0.7 + 1.3), including prevention of death in 0.8 percent. CVA = cerebrovascular accident (stroke).",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hebert PR, Moser M, Mayer J, et al. Arch Intern Med 1993; 153:578.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44509=[""].join("\n");
var outline_f43_29_44509=null;
var title_f43_29_44510="PIP contracture in scleroderma";
var content_f43_29_44510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal interphalangeal flexion contractures in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin breakdown (arrow) over the distal interphalangeal joint of the small finger can be observed in a patient with systemic sclerosis and proximal interphalangeal flexion contractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44510=[""].join("\n");
var outline_f43_29_44510=null;
var title_f43_29_44511="Severe otitis externa";
var content_f43_29_44511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe otitis externa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 220px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complete ear canal closure and auricular erythema extending to periauricular tissue, including the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laura A Goguen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_29_44511=[""].join("\n");
var outline_f43_29_44511=null;
